

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
5 July 2001 (05.07.2001)

PCT

(10) International Publication Number  
**WO 01/47897 A1**

(51) International Patent Classification<sup>7</sup>: **C07D 237/04**,  
A61K 31/505, A61P 29/00, C07D 401/12, A61K 31/53,  
C07D 403/04, A61K 31/55, C07D 403/12

(21) International Application Number: PCT/US00/35289

(22) International Filing Date:  
22 December 2000 (22.12.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/173,227 28 December 1999 (28.12.1999) US

(71) Applicants: **PHARMACOEPIA, INC.** [US/US]; 3000  
Eastpark Boulevard, Cranbury, NJ 08512 (US). **BRIS-**  
**TOL-MYERS SQUIBB COMPANY** [US/US]; P.O.  
Box 4000, Lawrenceville-Princeton Road, Princeton, NJ  
08543-4000 (US).

(72) Inventors: **MORIARTY, Kevin, Joseph**; 3008 Green-  
ridge Drive, Norristown, PA 19403 (US). **SHIMSHOCK,**  
**Yvonne**; 13 Banor Drive, Hillsborough, NJ 08844 (US).  
**AHMED, Gulzar**; 2017 Polo Run Drive, Yardley, PA  
19067 (US). **WU, Junjun**; 1115 Raven's Crest Drive,  
Plainsboro, NJ 08536 (US). **WEN, James**; 12 Scenic  
Drive, Dayton, NJ 08810 (US). **LI, Wei**; 25 Lexington  
Drive, Acton, MA 01720 (US). **ERICKSON, Shawn,**  
**David**; 122 Oaktree Place, Leonia, NJ 07605 (US).

**LETOURNEAU, Jeffrey, John**; 17222 Travis Court,  
Princeton Junction, NJ 08550 (US). **MCDONALD,**  
**Edward**; 1 Alvarmar Court, Skillman, NJ 08558 (US).  
**LEFTHERIS, Katerina**; 92 Richmond Drive, Skillman,  
NJ 08558 (US). **WROBLESKI, Stephen, T.**; 1507 South  
Branch Drive, Whitehouse Station, NJ 08889 (US).

(74) Agents: **DAVIS, Stephen, B.** et al.; Bristol-Myers Squibb  
Company, P.O. Box 4000, Lawrenceville-Princeton Road,  
Princeton, NJ 08543-4000 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,  
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,  
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,  
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,  
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,  
TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).


**Published:**

— With international search report.

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.

WO 01/47897 A1

(54) Title: CYTOKINE, ESPECIALLY TNF-ALPHA, INHIBITORS



(57) Abstract: N-heterocyclic compounds that block cytokine production via inhibition of p38 ki-  
nase are disclosed. In one embodiment, compounds of the present invention are represented by  
Formula I. Methods of production, pharmaceutical compositions and methods of treating conditions  
associated with inappropriate p38 kinase activity or TNF- $\alpha$  expression utilizing compounds of the  
present invention are also disclosed.

CYTOKINE, ESPECIALLY TNF- $\alpha$ , INHIBITORS

This invention relates to N-heterocyclic compounds that are effective in blocking cytokine production, and in particular the expression of TNF- $\alpha$  (TNF- $\alpha$ ), via inhibition of p38 kinase. Compounds of the present invention are useful in the treatment of inflammatory diseases such as, for example, rheumatoid arthritis.

Overproduction of cytokines such as IL-1 and TNF- $\alpha$  is implicated in a wide variety of inflammatory diseases, including rheumatoid arthritis (RA), psoriasis, multiple sclerosis, inflammatory bowel disease, endotoxin shock, osteoporosis, Alzheimer's disease and congestive heart failure, among others [Henry *et al.*, *Drugs Fut.*, 24:1345-1354 (1999); Salituro *et al.*, *Curr. Med. Chem.*, 6:807-823 (1999)]. There is convincing evidence in human patients that protein antagonists of cytokines, such as, for example, monoclonal antibody to TNF- $\alpha$  (Enbrel) [Rankin *et al.*, *Br. J. Rheumatol.*, 34:334-342 (1995)], soluble TNF- $\alpha$  receptor-Fc fusion protein (Etanercept) [Moreland *et al.*, *Ann. Intern. Med.*, 130:478-486 (1999)] and or IL-1 receptor antagonist [Bresnihan *et al.*, *Arthritis Rheum.*, 41:2196-2204 (1998)], can provide effective treatment for chronic inflammatory diseases. As none of the current treatments for inflammatory diseases provide complete relief of symptoms, and as most current treatments are associated with various drawbacks such as side effects, improved methods for treating inflammatory diseases are desirable.

TNF- $\alpha$  is a protein whose synthesis occurs in many cell types in response to an external stimulus, such as, for example, a mitogen, an infectious organism, or trauma. Signaling from the cell surface to the nucleus proceeds via several intracellular mediators including kinases that catalyze phosphorylation of proteins downstream in the signaling cascade. Important mediators for the production of TNF- $\alpha$  cytokine are the mitogen-activated protein (MAP) kinases, and in particular, p38 kinase.

p38 Kinases are activated in response to various stress stimuli, including, but not limited to, proinflammatory cytokines, endotoxin, ultraviolet light, and osmotic shock. Activation of p38 requires dual phosphorylation by upstream MAP kinase kinases (MKK3 and MKK6) on threonine and tyrosine within a Thr-Gly-Tyr motif, characteristic of p38 isozymes.

Four iso-forms of p38 have been described. The  $\alpha$  and  $\beta$  forms are expressed in inflammatory cells and are thought to be key mediators of TNF- $\alpha$  production. Inhibition of the enzymes p38 $\alpha$  and  $\beta$  in cells results in reduced levels of expression of TNF- $\alpha$ , and such inhibitors are effective in animal models of inflammatory disease.

Molecular cloning of human p38 $\alpha$  identified two isozymes, which are the splice variant product of a single gene. Three additional gene products have subsequently been identified, p38 $\beta$ , p38 $\gamma$ , and p38 $\delta$ . p38 kinases phosphorylate and activate the transcription factors, ATF-2, MAX, CHOP, and C/ERF, suggesting a role of p38 kinases in gene regulation. In addition, p38 kinases phosphorylate other protein kinases, such as MAPK activated protein kinase-2/3 (MAPKAP-K2/3, or MK2/3), and MAP-kinase-interacting kinase 1/2 (MNK1/2). Recently, activation of MK2 has been shown to be essential for LPS-induced TNF- $\alpha$  expression [Kotlyarov *et al.*, *Nature Cell Biol.*, 1:94-97 (1999)]. Mice lacking MK2 exhibit a 90% reduction in the production of TNF- $\alpha$  and are resistant to shock induced by LPS. The reduction in TNF- $\alpha$  amounts is due not to decreased production of the TNF- $\alpha$  mRNA, but rather to diminished production of the TNF- $\alpha$  protein, suggesting that MK2 regulates biosynthesis of TNF- $\alpha$  at a post-transcriptional level.


Ample evidence indicates that the p38 pathway serves an important role in inflammatory process mediated by IL-1 and TNF- $\alpha$ .

Small molecule inhibitors of p38 are expected to have several advantages over protein inhibitors of TNF- $\alpha$  or IL-1. p38 inhibitors not only block the production of TNF- $\alpha$  and IL-1, but also directly interfere with many of their secondary biological effects. In addition, small molecule inhibitors are unlikely to induce immune reaction in patients, and are believed active following oral administration.

The present invention provides novel compounds that are potent and selective inhibitors of p38 $\alpha$  and  $\beta$ , and as such, are also potent inhibitors of TNF- $\alpha$  expression in human cells. Compounds of the present invention are useful in the treatment of p38- and TNF- $\alpha$  expression-mediated inflammatory and other disorders, including, but not limited to, bone resorption, graft vs. host reaction, atherosclerosis, arthritis, osteoarthritis, rheumatoid arthritis, gout, psoriasis, topical inflammatory disease states, adult respiratory distress syndrome, asthma, chronic pulmonary inflammatory disease, cardiac reperfusion injury, renal reperfusion injury, thrombus, glomerulonephritis, Crohn's disease, ulcerative colitis, inflammatory bowel disease, multiple sclerosis, endotoxin shock, osteoporosis, Alzheimer's disease, congestive heart failure and cachexia.

The compounds of the present invention are effective as inhibitors of inappropriate p38 activity, especially iso forms  $\alpha$  and  $\beta$ , and in turn, of cytokine production, and in particular, of cellular TNF- $\alpha$  (TNF- $\alpha$ ) expression. Accordingly, compounds of the invention are useful for the inhibition, prevention and suppression of various pathologies associated with such activity, such as, for example, inflammation, asthma, arthritis, atherosclerosis, multiple sclerosis, psoriasis, autoimmune diseases, Alzheimer's disease and congestive heart failure, among others.

In one embodiment, the principles of the present invention provide a compound, or a salt thereof, represented by Formula I:



wherein:

V is chosen from  $-\text{CHR}^5$ -,  $-\text{NR}^5$ -,  $-\text{O}$ -, and  $-\text{S}$ -;

W, X, and Y are independently chosen from  $-\text{CH}=\text{}$  and  $-\text{N}=\text{}$ ;

Z is chosen from halogen, alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, heteroaryl, substituted heteroaryl,  $-\text{SR}^3$ ,  $-\text{O-R}^3$ , and  $-\text{N(R}^1\text{)(R}^2\text{)}$ ;



$-N(R^1)(R^2)$  taken together can form a heteroaryl, substituted heteroaryl, heterocyclyl or substituted heterocyclyl or


$R^1$  is chosen from hydrogen, alkyl and substituted alkyl; and

$R^2$  is chosen from hydrogen, alkyl, substituted alkyl, alkoxy, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, heteroaryl, and substituted heteroaryl;

$R^3$  is chosen from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, heteroaryl and substituted heteroaryl;

$R^5$  is chosen from hydrogen and alkyl;

$R^6$  is



$R^7$  is chosen from hydrogen,  $-N(R^{31})(R^{32})$ , halogen, cyano, alkyl, substituted alkyl, alkoxy, and alkylthio;

$R^8$  is chosen from hydrogen and halogen;

$R^9$  is chosen from nitro, carboxy,  $-C(O)N(R^{31})(R^{32})$ ,  $-SO_2N(R^{31})(R^{32})$ ,  $-N(R^{33})SO_2R^{34}$ ,  $-C(O)N(R^{33})N(R^{31})(R^{32})$ ,  $-N(R^{33})C(O)R^{34}$ ,  $-CH_2N(R^{33})C(O)R^{34}$ ,  $-N(R^{31})(R^{32})$ ,  $-CH_2OC(O)R^{34}$ , alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heterocyclyl, substituted heterocyclyl, heteroaryl, substituted heteroaryl and  $-C(O)R^{10}$ ;

$R^{10}$  is chosen from heterocyclyl, substituted heterocyclyl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, alkyl, substituted alkyl, and  $-N(R^{31})(R^{32})$ ; or

$R^8$  and  $R^9$  taken together may form  $-C(O)N(R^{33})CH_2-$  or  $-C(O)N(R^{33})C(O)-$ ;

$R^{31}$  and  $R^{33}$  are independently chosen from hydrogen, alkyl, and substituted alkyl;

$R^{32}$  is chosen from hydrogen, alkyl, substituted alkyl, alkoxy, aryl, substituted aryl, cycloalkyl, aryloxy, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, heteroaryl and substituted heteroaryl;

$R^{34}$  is chosen from alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, heteroaryl, and substituted heteroaryl;

when V is  $-NR^5$ ,  $-N(R^5)(R^6)$  taken together may form heterocyclyl, substituted heterocyclyl, heteroaryl, or substituted heteroaryl;


$R^{11}$  is chosen from halogen,  $O-R^{13}$  and  $-N(R^{12})(R^{13})$ ;

$R^{12}$  is chosen from hydrogen, alkyl, and substituted alkyl;

$R^{13}$  is  $-(CH_2)_mR^{14}$ ;


m is 0, 1, 2 or 3;

$R^{14}$  is chosen from hydrogen, alkyl, substituted alkyl,  $-C(O)N(R^{31})(R^{32})$ ,  $-N(R^{33})C(O)R^{34}$ , aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, heteroaryl, substituted heteroaryl, and



$R^{15}$  is chosen from hydrogen, alkyl, substituted alkyl, alkenyl,  $-C(O)$ -alkyl,  $-C(O)$ -substituted alkyl,  $-C(O)$ -aryl,  $-C(O)$ -substituted aryl,  $-C(O)$ -alkoxy, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, heteroaryl, and substituted heteroaryl;

$R^{16}$  is chosen from hydrogen, alkyl, substituted alkyl, and



$R^{17}$  is chosen from hydrogen, alkyl, substituted alkyl,  $-C(O)$ -alkyl,  $-C(O)$ -substituted alkyl,  $-C(O)$ -aryl, and  $-C(O)$ -substituted aryl; or

$-N(R^{12})(R^{13})$  taken together may form heterocyclyl, substituted heterocyclyl, heteroaryl, or substituted heteroaryl.

The principles of the present invention also provide methods of inhibiting TNF- $\alpha$  expression in a mammal, wherein the methods comprise administering to the mammal an effective amount of a compound represented by Formula I, or a prodrug or salt thereof. As used herein, inhibiting TNF- $\alpha$  expression is intended to include inhibiting, suppressing and

preventing conditions associated with inappropriate TNF- $\alpha$  expression, including, but not limited to, inflammation, asthma, arthritis, atherosclerosis, multiple sclerosis, psoriasis, autoimmune diseases, Alzheimer's disease and congestive heart failure.

The principles of the present invention further provide methods of treating p38 kinase and TNF- $\alpha$  mediated disorders in a mammal, the methods comprising administering to a mammal in need of such treatment, an effective amount of a compound represented by Formula I, or a prodrug or salt thereof. As used herein, a p38 kinase mediated disorder means a disorder associated with inappropriate p38 kinase activity; a TNF- $\alpha$  mediated disorder means a disorder associated with inappropriate TNF- $\alpha$  expression. Such disorders include, but are not limited to, inflammation, asthma, arthritis, atherosclerosis, multiple sclerosis, psoriasis, autoimmune diseases, Alzheimer's disease and congestive heart failure.

Accordingly, the compounds of the invention, as well as prodrugs or salts thereof, may be used in the manufacture of a pharmaceutical composition or medicament for the prophylactic or therapeutic treatment of disease states in mammals. The compounds of the present invention may be administered as pharmaceutical compositions as a monotherapy, or in combination with, for example, other anti-inflammatory, *e.g.* a steroid or NSAID (non-steroidal anti-inflammatory drug) and/or immunosuppressive agents. Such combination therapies can involve the administration of the various pharmaceuticals as a single dosage form or as multiple dosage forms administered simultaneously or sequentially.

Any suitable route of administration may be employed for providing a patient with an effective amount of a compound of the present invention. Suitable routes of administration may include, for example, oral, rectal, nasal, buccal, parenteral (such as, intravenous, intrathecal, subcutaneous, intramuscular, intrasternal, intrahepatic, intralesional, intracranial, intra-articular, and intra-synovial), transdermal (such as, for example, patches), and the like. Due to their ease of administration, oral dosage forms, such as, for example, tablets, troches, dispersions, suspensions, solutions, capsules, soft gelatin capsules, and the like, may be preferred. Administration may also be by controlled or sustained release means and delivery devices. Methods for the preparation of such dosage forms are well known in the art.

Pharmaceutical compositions incorporating compounds of the present invention may include excipients, a pharmaceutically acceptable carrier, in addition to other therapeutic ingredients. Excipients such as starches, sugars, microcrystalline cellulose, diluents, lubricants, binders, coloring agents, flavoring agents, granulating agents, disintegrating agents, and the like may be appropriate depending upon the route of administration. Because of their ease of administration, tablets and capsules represent the most advantageous oral dosage unit forms. If desired, tablets may be coated by standard aqueous or nonaqueous techniques.

The compounds of the present invention may be used in the form of pharmaceutically acceptable salts derived from inorganic or organic bases, and hydrates thereof. Included among such base salts are ammonium salts, alkali metal salts, such as sodium and potassium salts, alkaline earth metal salts, such as calcium and magnesium salts, salts with organic bases, such as dicyclohexylamine salts, *N*-methyl-*D*-glucamine, and salts with amino acids such as arginine, lysine, and so forth.

Abbreviations & Definitions

The following terms and abbreviations retain the indicated meaning throughout this disclosure.

ATP	=	adenosine triphosphate
cDNA	=	complementary DNA
DCE	=	dichloroethylene
DCM	=	dichloromethane = methylene chloride = CH <sub>2</sub> Cl <sub>2</sub>
DIC	=	diisopropylcarbodiimide
DIEA	=	<i>N,N</i> -diisopropylethylamine
DMF	=	<i>N,N</i> -dimethylformamide
DMSO	=	dimethyl sulfoxide
DTT	=	dithiothreitol
EDTA	=	ethylenediaminetetraacetic acid
EIA	=	enzyme immunoassay
ELISA	=	enzyme-linked immunosorbent assay
Fmoc	=	9-fluorenylmethoxycarbonyl
GST	=	glutathione S-transferase
HOBt	=	1-hydroxybenzotriazole
LPS	=	lipopolysaccharide
MBP	=	myelin basic protein
MES	=	2-( <i>N</i> -morpholino)ethanesulfonic acid
mRNA	=	messenger RNA
PCR	=	polymerase chain reaction
Pr <sub>2</sub> NEt	=	dipropylethylamine
<i>i</i> -Pr <sub>2</sub> NEt	=	diisopropylethylamine
RPMI	=	Roswell Park Memorial Institute
TBS	=	<i>t</i> -butyldimethylsilyl
TFA	=	trifluoroacetic acid
THF	=	tetrahydrofuran

"Alkyl" is intended to include linear or branched hydrocarbon structures and combinations thereof of 1 to 20 carbons. "Lower alkyl" means alkyl groups of from 1 to about 10, preferably from 1 to about 8, and more preferably, from 1 to about 6 carbon atoms. Examples of such radicals include methyl, ethyl, *n*-propyl, isopropyl, *n*-butyl, isobutyl, *s*-butyl, *t*-butyl, pentyl, *iso*-amyl, hexyl, octyl and the like.

"Aryl" means an aromatic hydrocarbon radical of 6 to about 16 carbon atoms, preferably of 6 to about 12 carbon atoms, and more preferably of 6 to about 10 carbon atoms. Examples of aryl groups are phenyl, which is preferred, 1-naphthyl and 2-naphthyl.

"Cycloalkyl" refers to saturated hydrocarbon ring structures of from 3 to 12 carbon atoms, and preferably from 3 to 6 carbon atoms. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, norbornyl, adamantyl, and the like. "Lower cycloalkyl" refers to cycloalkyl of 3 to 6 carbons.

"Heterocyclyl" refers to saturated or partially saturated monocyclic structures of from 3 to 8 atoms, preferably 5 or 6 atoms, and bicyclic structures of 9 or 10 atoms containing one or more carbon atoms and from 1 to 4 heteroatoms chosen from O, N, and S. "Heteroaryl" refers to unsaturated structures of 5 to 6 atoms and bicyclic structures of 9 or 10 atoms containing one or more carbons and from 1 to 4 heteroatoms chosen from O, N and S. The point of attachment of the heterocyclyl or heteroaryl structure is at an available carbon or nitrogen atom. Examples include: imidazole, pyridine, indole, thiophene, benzopyranone, thiazole, furan, benzimidazole, quinoline, isoquinoline, quinoxaline, pyrimidine, pyrazine, tetrazole, pyrazole, pyrrolyl, pyridinyl, pyrazolyl, triazolyl, pyrimidinyl, pyridazinyl, oxazolyl, thiazolyl, imidazolyl, indolyl, thiophenyl, furanyl, tetrazolyl, 2-pyrrolyl, 3-pyrrolyl, pyrrolidinyl, 1,3-dioxolanyl, imidazolinyl, imidazolidinyl, pyrazolinyl, pyrazolidinyl, isoxazolyl, isothiazolyl, 1,2,3-oxadiazolyl, 1,2,3-triazolyl, 1,3,4-thiadiazolyl, 2H-pyranyl, 4H-pyranyl, piperidinyl, 1,4-dithianyl, thiomorpholinyl, pyrazinyl, piperazinyl, 1,3,5-triazinyl, 1,2,5-trithianyl, benzo(b)thiophenyl, benzimidazolyl, quinolinyl, and the like.

"Alkoxy" means a straight, branched or cyclic hydrocarbon configuration and combinations thereof, including from 1 to 20 carbon atoms, preferably from 1 to 8 carbon


atoms, more preferably from 1 to about 4 carbon atoms, and an oxygen atom at the point of attachment. Suitable alkoxy groups include methoxy, ethoxy, *n*-propoxy, isopropoxy, *n*-butoxy, *iso*-butoxy, *s*-butoxy, *t*-butoxy, cyclopropyloxy, cyclohexyloxy, and the like. "Lower alkoxy" refers to alkoxy groups having from 1 to 4 carbon atoms. Similarly, "alkylthio" refers to such groups having a sulfur atom at the point of attachment.

"Alkenyl" refers to an unsaturated acyclic hydrocarbon radical in so much as it contains at least one double bond. "Lower alkenyl" refers to such radicals containing from about 2 to about 10 carbon atoms, preferably from about 2 to about 8 carbon atoms and more preferably 2 to about 6 carbon atoms. Examples of suitable alkenyl radicals include propenyl, buten-1-yl, isobutenyl, penten-1-yl, 2-methylbuten-1-yl, 3-methylbuten-1-yl, hexen-1-yl, hepten-1-yl, and octen-1-yl, and the like.

"Alkynyl" refers to an unsaturated acyclic hydrocarbon radical containing at least one triple bond. Examples include ethynyl, propynyl, and the like.

"Substituted alkyl" means an alkyl wherein one or more hydrogens, preferably one, two, or three hydrogens, attached to an aliphatic carbon are replaced with a substituent such as  $-N(R^{31})(R^{32})$ , alkoxy, alkylthio, halogen, cyano, carboxyl, hydroxyl,  $-SO_2$ -alkyl,  $-CO_2$ -alkyl,  $-C(O)$ -alkyl, nitro, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heterocyclyl, substituted heterocyclyl, heteroaryl, substituted heteroaryl,  $-C(O)-N(R^{31})(R^{32})$ , or  $-NH-C(O)$ -alkyl. Examples of such substituent groups include methoxy, ethoxy, propoxy, amino, methylamino, dimethylamino, phenyl naphthyl, chlorine, fluorine, and the like.

"Substituted cycloalkyl" means a cycloalkyl wherein one or more hydrogens, preferably one, two or three hydrogens, attached to a ring carbon are replaced with a substituent such as alkyl, substituted alkyl,  $-N(R^{31})(R^{32})$ , alkoxy, alkylthio, aryl, substituted aryl, halogen, cyano, carboxyl, hydroxyl, nitro,  $-SO_2$ -alkyl,  $-CO_2$ -alkyl,  $-C(O)$ -alkyl,  $-C(O)-N(R^{31})(R^{32})$ , or  $-NH-C(O)$ -alkyl. Examples of such groups include methyl, isopropyl, methoxy, ethoxy, propoxy, amino, methylamino, dimethylamino, phenyl, chlorine, fluorine and the like. Also included within this definition are cycloalkyl rings having a fused aryl, preferably phenyl, or cycloalkyl such as



and the like.

“Substituted aryl” means an aryl wherein one or more hydrogens, preferably one, two or three hydrogens, attached to an aromatic carbon are replaced with a substituent such as alkyl, substituted alkyl,  $-N(R^{31})(R^{32})$ , alkoxy, alkylthio, aryl, substituted aryl, halogen, cyano, nitro, carboxyl, hydroxyl,  $-SO_2$ -alkyl,  $-CO_2$ -alkyl,  $-C(O)$ -alkyl,  $-C(O)-N(R^{31})(R^{32})$ , or  $-NH-C(O)$ -alkyl. Examples of such substituents include methyl, isopropyl, methoxy, ethoxy, propoxy, amino, methylamino, dimethylamino, phenyl, chlorine, fluorine,  $-CO_2CH_3$ ,  $-C(O)-NH_2$ , and the like.

“Substituted heteroaryl” or “substituted heterocyclyl” means a heteroaryl or heterocyclyl substituted at one or more available carbon or nitrogen atoms, preferably at one or two carbon and/or nitrogen atoms, with a substituent such as alkyl, substituted alkyl,  $-N(R^{31})(R^{32})$ , alkoxy, alkylthio, aryl, substituted aryl, halogen, cyano, nitro, oxo, carboxyl, hydroxyl,  $-SO_2$ -alkyl,  $-CO_2$ -alkyl,  $-C(O)$ -alkyl,  $-C(O)-N(R^{31})(R^{32})$ , or  $-NH-C(O)$ -alkyl. Examples of such groups include methyl isopropyl, methoxy, ethoxy, propoxy, amino, methylamino, dimethylamino, phenyl, chlorine, fluorine and the like.

“Halogen” is intended to include for example, F, Cl, Br and I.

The term “prodrug” refers to a chemical compound that is converted to an active agent by metabolic processes *in vivo*. [See, e.g., N. Boder and J.J. Kaminski, *Ann. Rep. Med. Chem.* 22:303 (1987) and H. Bundgaard, *Adv. Drug Delivery Rev.*, 3:39 (1989)]. With regard to the present invention, a prodrug of a compound of Formula I is intended to mean any compound that is converted to a compound of Formula I by metabolic processes *in vivo*. The use of prodrugs of compounds of Formula I in any of the methods described herein is contemplated and is intended to be within the scope of the invention.

Terminology related to “protected,” “protecting” and/or “deprotecting” functionalities is used throughout this application. Such terminology is well understood by persons of skill in the art and is used in the context of processes which involve sequential



treatment with a series of reagents. In this context, a protecting group refers to a group which is used to mask a functionality during a process step in which it would otherwise react, but in which reaction is undesirable. The protecting group prevents reaction at that step, but may be subsequently removed to expose the original functionality. The removal or "deprotection" occurs after the completion of the reaction or reactions in which the functionality would interfere. Thus, when a sequence of reagents is specified, as it is in the processes of the invention, the person of ordinary skill can readily envision those groups that would be suitable as "protecting groups" for the functionalities involved.

In the case of the present invention, the typical functionalities that must be protected are amines. Suitable groups for that purpose are discussed in standard textbooks in the field of chemistry, such as Protective Groups in Organic Synthesis by T.W. Greene [John Wiley & Sons, New York, 1991], which is incorporated herein by reference. Particular attention is drawn to the chapter entitled "Protection for the Amino Group" (pages 309-405). Preferred protecting groups include BOC and Fmoc. Exemplary methods for protecting and deprotecting with these groups are found in Greene and Wuts on pages 318 and 327.

The materials upon which the syntheses described herein are performed are referred to as solid supports, beads, and resins. These terms are intended to include: (a) beads, pellets, disks, fibers, gels, or particles such as cellulose beads, pore-glass beads, silica gels, polystyrene beads optionally cross-linked with divinylbenzene and optionally grafted with polyethylene glycol, poly-acrylamide beads, latex beads, dimethylacrylamide beads optionally cross-linked with *N,N'*-bis-acryloyl ethylene diamine, glass particles coated with hydrophobic polymer, etc., i.e., material having a rigid or semi-rigid surface; and (b) soluble supports such as polyethylene glycol or low molecular weight, non-cross-linked polystyrene. The solid supports may, and usually do, have functional groups such as amino, hydroxy, carboxyl, or halo groups; where amino groups are the most common.

TentaGel™ NH<sub>2</sub> (Rapp Polymere, Tubingen, Germany) is a preferred amine functionalized polyethylene glycol-grafted polystyrene resin. TentaGel™-S-PHB resin has a para-hydroxy benzyl linker which can be cleaved by the use of 90% trifluoroacetic acid in DCM. Techniques for functionalizing the surface of solid

phases are well known in the art. Attachment of lysine to the amino groups on a bead (to increase the number of available sites) and subsequent attachment of linkers as well as further steps in a typical combinatorial synthesis are described, for example, in PCT application WO95/30642, the disclosure of which is incorporated herein by reference. In the synthesis described in WO95/30642, the linker is a photolytically cleavable linker, but the general principles of the use of a linker are well illustrated.

#### Optical Isomers - Diastereomers - Geometric Isomers

Some of the compounds described herein contain one or more asymmetric centers and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms which may be defined in terms of absolute stereochemistry as (*R*)- or (*S*)-, or as (*D*)- or (*L*)- for amino acids. The present invention is meant to include all such possible diastereomers as well as their racemic and optically pure forms. Optically active (*R*)- and (*S*)-, or (*D*)- and (*L*)- isomers may be prepared using chiral synthons or chiral reagents, or optically resolved using conventional techniques. When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless specified otherwise, it is intended to include both (*E*)- and (*Z*)- geometric isomers. Likewise, all tautomeric forms are intended to be included.

Compounds of the invention which incorporate chiral diamines may be resolved into pairs of enantiomers by known techniques. Where pure enantiomers of starting materials are not commercially available, they may be obtained by classic resolution, which may employ, for example, fractional crystallization of diastereomeric salts. Compounds of the invention may have more than one chiral center, for example wherein reductive amination of a homochiral intermediate leads to a mixture of diastereomers. Racemic intermediates and compounds of the invention may also be resolved by chromatographic separation, such as for example, HPLC using a column loaded with a homochiral support, to yield pure isomeric compounds.

The configuration of any carbon-carbon double bond appearing herein is selected for convenience only and is not intended to designate a particular configuration; thus a carbon-carbon double bond depicted arbitrarily herein as *trans* may be *cis*, *trans*, or a mixture of the two in any proportion.

In view of the above definitions, other chemical terms used throughout this application can be easily understood by those of skill in the art. Terms may be used alone or in any combination thereof. The preferred and more preferred chain lengths of the radicals apply to all such combinations.

#### Utility

The compounds of the present invention have demonstrated utility as selective inhibitors of inappropriate p38 kinase activity, and in particular, isoforms p38 $\alpha$  and p38 $\beta$ . As such, compounds of the present invention have utility in the treatment of conditions associated with inappropriate p38 kinase activity. Such conditions include diseases in which cytokine levels are modulated as a consequence of intracellular signaling via p38, and in particular, diseases that are associated with an overproduction of such cytokines as IL-1, IL-4, IL-8, and in particular, TNF- $\alpha$ .

As inhibitors of p-38 kinase activity, compounds of the present invention are useful in the treatment and prevention of p-38 mediated conditions including, but not limited to, inflammatory diseases, autoimmune diseases, destructive bone disorders, proliferative disorders, angiogenic disorders, infectious diseases, neurodegenerative diseases, viral diseases, allergies, myocardial ischemia, reperfusion/ischemia in stroke, heart attacks, organ hypoxia, vascular hyperplasia, cardiac hypertrophy, thrombin-induced platelet aggregation, and conditions associated with prostaglandin endoperoxidase synthase-2.

Inflammatory diseases which may be treated or prevented include, but are not limited to, acute pancreatitis, chronic pancreatitis, asthma, allergies and adult respiratory distress syndrome.

Autoimmune diseases which may be treated or prevented include, but are not limited to, glomerulonephritis, rheumatoid arthritis, systemic lupus erythematosus, scleroderma, chronic thyroiditis, Grave's disease, autoimmune gastritis, diabetes, autoimmune hemolytic anemia, autoimmune neutropenia, thrombocytopenia, atopic

dermatitis, chronic active hepatitis, myasthenia gravis, multiple sclerosis, inflammatory bowel disease, ulcerative colitis, Crohn's disease, psoriasis, or graft vs. host disease.

Destructive bone disorders which may be treated or prevented include, but are not limited to, osteoporosis, osteoarthritis and multiple myeloma-related bone disorder.

Proliferative diseases which may be treated or prevented include, but are not limited to, acute myelogenous leukemia, chronic myelogenous leukemia, metastatic melanoma, Kaposi's sarcoma, and multiple myeloma.

Infectious diseases which may be treated or prevented include, but are not limited to, sepsis, septic shock, and Shigellosis.

Neurodegenerative diseases which may be treated or prevented by the compounds of this invention include, but are not limited to, Alzheimer's disease, Parkinson's disease, cerebral ischemias or neurodegenerative disease caused by traumatic injury.

Angiogenic disorders which may be treated or prevented include solid tumors, ocular neovascularization, infantile haemangiomas.

Viral diseases which may be treated or prevented include, but are not limited to, acute hepatitis infection (including hepatitis A, hepatitis B and hepatitis C), HIV infection and CMV retinitis.

In addition, p38 inhibitors of this invention also exhibit inhibition of the expression of inducible pro-inflammatory proteins such as prostaglandin endoperoxide synthase-2 (PGHS-2), also referred to as cyclooxygenase-2 (COX-2). Accordingly, additional p38 mediated conditions include edema, analgesia, fever and pain, such as neuromuscular pain, headache, pain caused by cancer, dental pain and arthritis pain.

As a result of their p38 inhibitory activity, compounds of the present invention have utility in the treatment and prevention of diseases associated with cytokine

production. For example, compounds of the present invention are useful in the treatment and prevention of:

IL-1 mediated diseases such as, for example, rheumatoid arthritis, osteoarthritis, stroke, endotoxemia and/or toxic shock syndrome, inflammatory reaction induced by endotoxin, inflammatory bowel disease, tuberculosis, atherosclerosis, muscle degeneration, cachexia, psoriatic arthritis, Reiter's syndrome, gout, traumatic arthritis, rubella arthritis, acute synovitis, diabetes, pancreatic  $\beta$ -cell disease and Alzheimer's disease;

IL-8 mediated diseases or conditions such as, for example, those characterized by massive neutrophil infiltration, such as psoriasis, inflammatory bowel disease, asthma, cardiac and renal reperfusion injury, adult respiratory distress syndrome, thrombosis and glomerulonephritis; and

TNF-mediated diseases or conditions such as rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions, sepsis, septic shock syndrome, adult respiratory distress syndrome, cerebral malaria, chronic pulmonary inflammatory disease, silicosis, pulmonary sarcoidosis, bone resorption disease, reperfusion injury, graft vs. host reaction, allograft rejections, fever and myalgias due to infection, cachexia secondary to infection, AIDS, ARC or malignancy, meloid formation, scar tissue formation, Crohn's disease, ulcerative colitis, pyresis, viral infections, such as HIV, CMV, influenza and herpes; and veterinary viral infections, such as lentivirus infections, including, but not limited to equine infectious anemia virus; or retro virus infections, including feline immunodeficiency virus, bovine immunodeficiency virus, or canine immunodeficiency virus.

The compounds of formula I including a pharmaceutically acceptable salt or hydrate thereof may be administered by any suitable route as described previously to treat the above mentioned diseases and conditions. The method of administration will, of course, vary depending upon the type of disease being treated. The amount of active compound administered will also vary according to the method of administration and the disease being treated. An effective amount will be within the dosage range of about 0.1 to

about 100 mg/kg, preferably about 0.2 to about 50 mg/kg, in a single or multiple doses administered at appropriate intervals throughout the day.

Preferred compounds of this invention are those of formula I including a pharmaceutically acceptable salt thereof wherein:

Two or more of W, Y and X are =N-;

V is  $-\text{CHR}^5$ -,  $-\text{NR}^5$ , or  $-\text{O}$ -;

Z is  $-\text{N}(\text{R}^1)(\text{R}^2)$ -,  $-\text{S}$ -aryl, or  $\text{S}$ -substituted aryl;

$\text{R}^1$  is hydrogen or alkyl;

$\text{R}^2$  is alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, heteroaryl, or substituted heteroaryl;

$\text{R}^5$  is hydrogen;

$\text{R}^7$  is hydrogen, alkyl, substituted alkyl, alkoxy, or halogen;

$\text{R}^8$  is hydrogen;

$\text{R}^9$  is  $-\text{C}(\text{O})\text{R}^{10}$ ;

$\text{R}^{10}$  is alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heterocyclyl, substituted heterocyclyl, heteroaryl, substituted heteroaryl, or  $-\text{N}(\text{R}^{31})(\text{R}^{32})$ ;

$\text{R}^{31}$  is hydrogen, alkyl, or substituted alkyl;

$\text{R}^{32}$  is hydrogen, alkyl, substituted alkyl, alkoxy, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, heteroaryl, or substituted heteroaryl;


$\text{R}^{11}$  is  $-\text{N}(\text{R}^{12})(\text{R}^{13})$ ;

$\text{R}^{12}$  is hydrogen, alkyl, or substituted alkyl;

$\text{R}^{13}$  is  $-(\text{CH}_2)_m\text{R}^{14}$ ;

m is 0, 1, 2 or 3;

$\text{R}^{14}$  is hydrogen, alkyl substituted alkyl,  $-\text{C}(\text{O})\text{N}(\text{R}^{31})(\text{R}^{32})$ -,  $-\text{N}(\text{R}^{33})\text{C}(\text{O})\text{R}^{34}$ -, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, heteroaryl, substituted heteroaryl or



$\text{R}^{15}$  is hydrogen, alkyl or substituted alkyl;

$R^{16}$  is hydrogen or alkyl; or

$-N(R^{12})(R^{13})$  taken together form heterocyclyl or substituted heterocyclyl;

$R^{33}$  is hydrogen, alkyl, or substituted alkyl; and

$R^{34}$  is alkyl, substituted alkyl, aryl or substituted aryl.

Most preferred compounds of this invention are those of formula I including a pharmaceutically acceptable salt thereof wherein:

Two or more of W, Y and X are =N-, especially where W, Y and X are each =N-;

V is -NH- or -O-;

Z is  $-N(R^1)(R^2)$ , -S-aryl, or -S-substituted aryl;

$R^1$  is hydrogen or alkyl of 1 to 4 carbons, especially methyl;

$R^2$  is alkyl of 1 to 8 carbons or substituted alkyl wherein said alkyl is of 1 to 8 carbons, especially alkyl of 4 to 8 carbons;

$R^7$  is hydrogen, alkyl of 1 to 4 carbons, alkoxy of 1 to 4 carbons, or halogen, especially hydrogen, methyl, methoxy, Cl, Br or F;

$R^8$  is hydrogen;

$R^9$  is  $-C(O)R^{10}$ ;

$R^{10}$  is  $-NH_2$ -, -NH-alkyl, -NH-alkoxy, -NH-phenyl, or  $-NH-CH_2$ -phenyl wherein alkyl and alkoxy are 1 to 6 carbons, especially  $-NH_2$ -, -NH- $CH_3$ -, -NH- $C_2H_5$ -, -NH- $OCH_3$ -, or -NH- $OC_2H_5$ ;

$R^{10}$  is  $-NH_2$ -, -NH-alkyl, or -NH-alkoxy wherein alkyl and alkoxy are of 1 to 6 carbons, especially methyl or methoxy;

$R^{11}$  is  $-N(R^{12})(R^{13})$  wherein  $N(R^{12})(R^{13})$  taken together form a monocyclic heterocyclyl or substituted heterocyclyl of 5 to 7 atoms containing 1 to 3 additional

nitrogen atoms or where  $R^{12}$  is hydrogen and  $R^{13}$  is alkyl of 1 to 4 carbons or especially wherein  $R^{11}$  is



The  $IC_{50}$  values (concentration required to inhibit 50% of specific binding) of compounds of the present invention for inhibition of p38 activity are below  $30 \mu M$ . Preferred compounds (exemplified by those of Table 1) have an  $IC_{50}$  below  $1 \mu M$ , more

preferred compounds have an  $IC_{50}$  below 300 nM and most preferred compounds have an  $IC_{50}$  below 100 nM.

Compounds shown in Tables 1-4 have been synthesized according to the methods described herein and have been tested in accordance with the protocols described below. These compounds are provided by way of illustration only, and the invention is not intended to be limited thereto.

#### Biological Assays

##### Generation of p38 Kinases

cDNAs of human p38 $\alpha$ ,  $\beta$  and  $\gamma$  isozymes were cloned by PCR. These cDNAs were subcloned in the pGEX expression vector (Pharmacia). GST-p38 fusion protein was expressed in *E. Coli* and purified from bacterial pellets by affinity chromatography using glutathione agarose. p38 fusion protein was activated by incubating with constitutively active MKK6. Active p38 was separated from MKK6 by affinity chromatography. Constitutively active MKK6 was generated according to Raingeaud *et al.* [*Mol. Cell. Biol.*, 1247-1255 (1996)].

##### TNF- $\alpha$ Production by LPS-Stimulated PBMCs

Heparinized human whole blood was obtained from healthy volunteers. Peripheral blood mononuclear cells (PBMCs) were purified from human whole blood by Ficoll-Hypaque density gradient centrifugation and resuspended at a concentration of  $5 \times 10^6$ /ml in assay medium (RPMI medium containing 10% fetal bovine serum). 50  $\mu$ l of cell suspension was incubated with 50  $\mu$ l of test compound (4X concentration in assay medium containing 0.2% DMSO) in 96 well-tissue culture plates for 5 minutes at room temperature. 100  $\mu$ l of LPS (200 ng/ml stock) was then added to the cell suspension and the plate was incubated for 6 hours at 37°C. Following incubation, the culture medium was collected and stored at -20°C. TNF $\alpha$  concentration in the medium was quantified using a standard ELISA kit (Pharmingen-San Diego, CA). Concentrations of TNF $\alpha$  and  $IC_{50}$  values for test compounds (concentration of compound that inhibited LPS-stimulated TNF $\alpha$  production by 50%) were calculated by linear regression analysis.



#### LPS-Induced TNF Production in THP-1 Cells

Human monocytic THP-1 cells were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum. Cells (40,000 cells in 80  $\mu$ l) were added to wells of 96-well flat-bottomed plates. Tested compounds (10  $\mu$ l) or vehicle (3 % DMSO) were added to wells. Subsequently, LPS (Sigma, #L7261; 10  $\mu$ l/well) was added to the cells for a final concentration of 1  $\mu$ g/mL. Plates were incubated overnight at 37° C and 5% CO<sub>2</sub>. Supernatant (50  $\mu$ l/well) was harvested for an ELISA assay. TNF was captured by an anti-human TNF antibody (R&D, #MAB610) which was pre-absorbed in high binding EIA plates (Costar, #3590). Captured TNF was recognized by a biotinlated anti-human TNF polyclonal antibody (R&D, #BAF210). Streptavidin conjugated with peroxidase was added to each well, and the activity of peroxidase was quantitated by a peroxide substrate kit (Pierce, #34062 and #34006).

#### p38 Assay

The assays were performed in V-bottomed 96-well plates. The final assay volume was 60  $\mu$ l prepared from three 20  $\mu$ l additions of enzyme, substrates (MBP and ATP) and test compounds in assay buffer (50 mM Tris pH 7.5, 10 mM MgCl<sub>2</sub>, 50 mM NaCl and 1 mM DTT). Bacterially expressed, activated p38 was pre-incubated with test compounds for 10 min. prior to initiation of reaction with substrates. The reaction was incubated at 25° C for 45 min. and terminated by adding 5  $\mu$ l of 0.5 M EDTA to each sample. The reaction mixture was aspirated onto a pre-wet filtermat using a Skatron Micro96 Cell Harvester (Skatron, Inc.), then wash with PBS. The filtermat was then dried in a microwave oven for 1 min., treated with MeltiLex A scintillation wax (Wallac), and counted on a Microbeta scintillation counter Model 1450 (Wallac). Inhibition data were analyzed by nonlinear least-squares regression using Prizm (GraphPad Software). The final concentration of reagents in the assays are ATP, 1  $\mu$ M; [ $\gamma$ -<sup>33</sup>P]ATP, 3 nM; MBP (Sigma, # M1891), 2  $\mu$ g/well; p38, 10 nM; and DMSO, 0.3%.


#### Methods of Synthesis

General methods of synthesis for compounds of the present invention are illustrated by the following examples. Compounds of the invention may be prepared by standard techniques known in the art, involving both solution and solid phase chemistry. Starting materials are commercially available or may be readily prepared by one of skill in


the art with known methods, or by methods disclosed herein. Specific embodiments described are presented by way of illustration only, and the invention is not limited thereto. Modifications and variations in any give material or process step will be readily apparent to one of skill in the art and all are to be included within the scope of the invention.

As illustrated in Scheme 1, compounds of Formula I wherein V is  $-NR^5-$ ; each of W, X and Y are N; and each of Z and  $R^{11}$  are attached to the core triazine by  $-N-$ , may be prepared from trichlorotriazine by sequential reactions with three different amines (1, 2, 3; 4 represents an N-substitution in amine 3). Preferably, one of the amines will be an aniline and another will be a diamine suitably protected on its distal N. The person of skill will recognize that the amines themselves, as well as the sequence of the three substitutions, may be varied, and are not limited by the particular example shown in Scheme 1.


Scheme 1




With respect to Formula I of the invention, Amine 1 corresponds to  $-N(R^5)(R^6)$ ; Amine 2 corresponds to  $-Z$ ; and Amine 3 corresponds to  $-R^{11}$  and such designations are used interchangeably in the description below.

Preparation of Amines 1 [-N(R<sup>5</sup>)(R<sup>6</sup>)]N,N-Dimethyl (3-amino-4-methyl)benzamide

3-Amino-4-methylbenzoic acid (9.06 g, 60 mmol) and NaOH (4.8 g, 120 mmol) were dissolved in 100 mL 50% acetone/water at 0°C. To the solution was added 13.2 g Boc<sub>2</sub>O (60 mmol) in acetone dropwise. The reaction was proceeded at 0°C for 30 min, then room temp for 3-4h. The solution was evaporated under vacuum, and the resulting aqueous solution was acidified by 2 N HCl to pH 2, and extracted subsequently with ethyl acetate. The organic layer was washed with water, 1 N HCl solution, saturated NaCl, dried over sodium sulfate. Filtration and evaporation under vacuum provided the desired intermediate (11.6 g, 77%).




The intermediate (5 g, 20 mmol) so obtained was dissolved in 40 mL THF. To the solution was added 2 N dimethylamine in THF (10 mL), DIC (3.13 mL, 20 mmol), and HOBt (2.7 g, 20 mmol). The solution was stirred at room temp for 16h and then filtered. The filtrates were evaporated under vacuum. The oily residue was purified by a flash column to afford 4.5 g of product (81%). Further treatment of the product with 20 mL of 50% TFA/DCM at room temp yielded the final desired product.

N-Methyl (3-amino-4-methyl) benzamide


Prepared according to the same protocol as above.

3-Amino-2methylbenzamide

The preparation was accomplished through a combination of solution phase and solid phase chemistry shown below.




*N*-Boc protection (2.03 g, 81%) was carried out following the same protocol described previously.



Rink amide resin (2 g, 0.4 mmol/g) in a reaction vessel was treated with 20 mL of 20% piperidine/DMF at room temp for 20 min. The resin was washed by DMF (4x). To this resin/DMF (5 mL) slurry was added Boc-3-amino-2-methylbenzoic acid (0.6 g, 2.4 mmol), HBTU (0.91 g, 2.4 mmol), HOBT (32 g, 2.4 mmol) and DIEA (0.43 mL, 2.4 mmol). The vessel was shaken at room temp for 2h. The resin was washed by DMF, CH<sub>3</sub>OH, and CH<sub>2</sub>Cl<sub>2</sub> successively. Subsequent treatment of the resin with 20 mL of 50% TFA/DCM yielded the desired product (66 mg, 55%).

### 3-Amino-4,5-dimethylbenzoic acid and 2-amino-3,4-dimethylbenzoic acid




To a solution of concentrated sulfuric acid (20 mL) was added 1.7 mL of nitric acid dropwise. The resultant solution was stirred at 0°C for 5 min and the 3,4-dimethylbenzoic acid (6 mg, 40 mmol) was added in several small portions. The reaction was proceeded at 0°C for 20 min, then room temp for 60 min. Cold water was added to the reaction mixture. The resulting precipitate was filtered, collected and purified by flash column.

The product was dissolved in 25 mL of CH<sub>3</sub>OH, and subjected to hydrogenation (10% Pd/C, H<sub>2</sub>, 50 psi) at room temp for 3-4h. Filtration and evaporation provided the desired products as a 1:1 mixture of Regio isomers (4 g, 61%).


Preparation of Amines 2 [-Z]

3-Methyl-3-n-propylpyrrolidine




$\alpha$ -Methyl- $\alpha$ -propyl-succinimide (310 mg, 2 mmol) was dissolved in THF and to the solution was added 84 mg LiAlH<sub>4</sub> (2.2 mmol) in three small portions. The reaction was proceeded at 0°C for 5 min, then room temp for 2h. Cold water was added to quench the reduction. The solution was filtered through celite. The filtrates were combined and evaporated under vacuum. The product (160 mg, Yield 63%) was ready for use.

4,4-Dimethylpiperidine



Prepared according to the same protocol as above.


Preparation of Amines 3 [-R<sup>11</sup>]




In a 500 mL flask, (3R)-(+)-3-aminopyrrolidine (10.0 g, 116 mmol) was dissolved in DCM (160 mL). The solution was added with benzophenone imine (1.0 equivalent) and stirred at room temp for 16 h. The solvent was removed under vacuum. The crude product was purified with flash chromatography to give the desired imine (24.3 g).

2.4 g of the imine obtained above was dissolved in DCM (30 mL). The solution was added with 2,6-lutidine (2.5 equivalents) and allyl chloroformate (1.2 equivalents) then cooled with ice. The reaction was stirred at room temp for 3 h, and concentrated under vacuum. The resulting mixture was added with ethyl acetate (100 mL) and aqueous ammonium chloride solution (20 mL). Separated from the organic layer, the aqueous layer was extracted with ethyl acetate twice. The combined organic layer was washed with saturated aq. ammonium chloride solution twice, brine twice, and dried with sodium sulfate, and then concentrated.

The above product was dissolved with methanol (30 mL). The solution was added with 0.4 N HCl (30 mL) after cooled with ice. Stirred at room temp for 2h, the reaction mixture was poured into water and washed with DCM (2x30 mL). Sodium carbonate solution was added to adjust the aqueous phase pH to 10, and the product was extracted with ethyl acetate (3x30 mL). The combined organic layer was washed with saturated aq. ammonium chloride solution twice, brine twice, and dried over sodium sulfate, and then concentrated to give the desired product (1.02 g, yield 63%). MS (m/z) calcd for  $C_8H_{14}N_2O_2$  (MH<sup>+</sup>), 171: found, 171.




To the solution of 3-(*t*-butoxycarbonylamino)-pyrrolidine (racemic, 745 mg, 4 mmol) in dichloroethane was added 2-pyridinecarboxaldehyde (0.38 mL, 4.0 mmol) and sodium triacetoxyborohydride (848 mg, 4 mmol). The solution was stirred at room temp for 2h. The solution was evaporated under vacuum. The oily residue was purified by flash column to afford 790 mg of pure product (71%). The product was further treated with 4 N HCl/dioxane to yield the final product as HCl salt.


1-(3-Methoxyethyl)-3-aminopyrrolidine

3-(*t*-Butoxycarbonylamino)-pyrrolidine (racemic, 932 mg, 5 mmol) and 2-methoxyacetic acid (0.39 mL, 5 mL.) were dissolved in DCM. To the solution was added 0.78 mL of DIC (5 mmol) and 675 mg HOBt (5 mmol). The reaction was proceeded at room temp for 16h. The solution was filtered. The filtrates were combined and evaporated under vacuum. The oily residue was purified by flash column to afford 843 mg of pure product (65%).


To a solution of the above intermediate (258 mg, 1 mmol) in THF was added 3mL of 1.0 M BH<sub>3</sub> in THF dropwise. The solution was stirred at 60°C for 3h and then cooled. Methanol was added. The solution was evaporated under vacuum. The resulting residue was extracted with ethyl acetate and saturated with sodium bicarbonate solution. The organic layer was washed with water, sat. sodium chloride solution and dried over sodium sulfate. The oily residue obtained by filtration and evaporation was further treated with 50% TFA/DCM at room temp for 30 min to afford 50 mg of final product (35%) as TFA salt.

1-(3-Methoxypropyl)-3-aminopyrrolidine


Prepared according to the same protocol as above.

*N*-*t*-Butyl pyrrolidine

*N*-Carbonylbenzyloxy-*L*-aspartic anhydride (2.49 g 10 mmol) and *t*-butyl amine (0.80 g, 10.9 mmol) were mixed in 5 mL of DMF. The mixture was stirred at room temp overnight, then it was heated in an oil bath at 120°C for 24h. The reaction mixture was partitioned between water and ethyl acetate. The organic layer was washed once with brine and dried over magnesium sulfate. Filtration, concentration, and purification by flash chromatography (solvent 6:4 hexane:ethyl acetate) provided 0.84 g (yield 28%) of product.




The product from the above step (0.54 g, 1.78 mmol) was dissolved in 5 mL anhydrous THF and cooled with an ice bath. Lithium aluminum hydride (1.0 M in THF, 4.5 mL) was added slowly. The mixture was stirred at 0°C for 3.5h, then quenched with water until hydrogen evolution ceased. The inorganic residue was filtered and washed with ethyl acetate. The combined filtrates were dried and evaporated to get 0.44 g (89%) of product.



The product from the previous step (180mg, 1.27 mol) was dissolved in 2 mL acetic acid and shaken with 10% Pd/C (18mg) under 60 psi hydrogen pressure for 2 h. the catalyst was filtered off and the filtrate was concentrated to give 120 mg of *t*-butyl-3-aminopyrrolidine acetic acid salt (91%).


#### 1-Phenyl-3-aminopyrrolidines




To a solution of 559 mg (3S)-3-(*t*-butoxycarbonylamino) pyrrolidine (3 mmol) in 5 mL DMSO was added 0.32 mL of 2-fluoro-1-nitrobenzene (3 mmol) and 0.52 mL DIEA (3 mmol). The solution was stirred at 100°C for 16h. The solution was cooled to room temp, diluted with water and extracted with ethyl acetate. The organic layer was washed with water, 1 N HCl solution, and saturated sodium chloride solution successively and dried




over sodium sulfate. Filtration, evaporation and purification by flash chromatography provided 660 mg desired product (72%).



The product (600 mg, 2 mmol) from the above was treated with 10 mL 50% TFA/DCM at room temp for 30 min. The solution was evaporated under vacuum. The oily residue was dissolved in acetone at 0°C. To the solution was added 777 mg of Fmoc-Cl (3 mmol) and 828 mg of potassium carbonate (6 mmol). The reaction was proceeded at 0°C for 30 min, then room temp for 16h. The solution was evaporated under vacuum. The residue was extracted with ethyl acetate and water. The organic layer was washed with water, saturated sodium chloride solution successively and dried over sodium sulfate. The solvent was removed and the product was purified by flash column. (680 mg, 79%)



The product (600 mg, 1.4 mmol) thus obtained was mixed with 249 mg of tin (2.1 mmol) in a 50 mL RB flask. To the mixture was added 10 mL of con. hydrogen chloride dropwise (ice water bath was needed if the reaction was too vigorous). The reaction was proceeded at room temp for 2h. Then 2 N NaOH aq. solution was added to the reaction mixture until the solution became basic. The resulting solution was extracted with ethyl acetate. The organic layer was washed with water, saturated sodium chloride solution, dried over sodium sulfate, and evaporated under vacuum. The crude product was purified by flash column to provide 130 mg of desired product along with 400 mg of recovered starting material.



The product (54 mg, 0.14 mmol) thus obtained was dissolved in 3 mL of absolute ethanol at 0°C. To the solution was added 0.22 mL of concentrated sulfuric acid, followed by 37 mg of sodium nitrite in 1 mL of water. The solution was stirred at 0°C for 5 min, then room temp for 60 min. Copper powder (87 mg, pre-washed with ether) was then added to the reaction solution. The solution was stirred at 60°C for 2-3h. After being

cooled down, the solution was extracted with ethyl acetate. The organic layer was washed with water, saturated sodium chloride solution, dried over sodium sulfate, filtered and evaporated under vacuum. The crude product was purified by flash column to afford 32 mg of product.


The product was further treated with 1 mL of 20% piperidine/DMF at room temp for 1h. The final product was purified by flash column (9 mg, 40%).

#### General Procedures for the Preparation of N-Substituted Pyrrolidines

The reductive aminations of the -NH group of Amines 3 were carried out at room temp in dichloroethane using 2-10 equivalents of aldehydes or ketones and sodium triacetoxyborohydride, NaHB(OAc)<sub>3</sub>. Separations after workup by chromatography were necessary for purification of the final product. The N-acylations and the N-alkylations via epoxide openings were carried out by procedures commonly used in the literature.


Compounds wherein V is -CHR<sup>5</sup>- may be prepared according to the following examples.

#### 3-{4-(5-Cyano-2-methyl-benzyl)-6-[(2,2-dimethyl-propyl)-methyl-amino]-[1,3,5]triazin-2-ylamino}-pyrrolidine-1-carboxylic acid tert-butyl ester



A suspension of **A** (0.036 g, 0.09 mmol), tetrakis(triphenylphosphine)-palladium(0) (0.025 g, 0.02 mmol), and 3-cyanobenzylzinc bromide (0.5 M in THF, 2 mL, 1 mmol) was stirred for 16h at 80°C in a sealed tube. After filtration and concentration of the solution, the product was purified by Prep-HPLC (36 mg, 81%, C<sub>27</sub>H<sub>39</sub>N<sub>7</sub>O<sub>2</sub>, MS m/z 494 (M+H)<sup>+</sup>).

3-[4-[(2,2-Dimethyl-propyl)-methyl-amino]-6-(pyrrolidin-3-ylamino)-  
[1,3,5]triazin-2-ylmethyl]-4-methyl-benzamide




A suspension of **B** (0.03 g, 0.06 mmol) in conc. sulfuric acid (4 mL) was stirred for 90 min at 60°C. After cooling to room temp, the reaction solution was diluted with water (20 mL), and basified with 6N aq. sodium hydroxide. The product was then extracted with ethyl acetate (2 x 20 mL). The combined organic layers were dried (anhyd. sodium sulfate), filtered and concentrated. The product was then purified by Prep-HPLC (5.2 mg, 21%, C<sub>22</sub>H<sub>33</sub>N<sub>7</sub>O, MS m/z 412 (M+H)<sup>+</sup>).


Compounds wherein V is -S- may be prepared according to the following examples.

Preparation of Thiophenols


Step 1: Compound A




To 3-hydroxy-4-methylbenzoic acid (2.0 g, 13 mmol) in anhydrous methanol (20 mL) at 0°C under argon was added thionyl chloride (1.4 mL, 20 mmol) dropwise over a period of 10 min. The mixture was stirred for 1 h at 0°C then room temp for overnight. The solvent was removed *in vacuo* and the residue was partitioned between ethyl acetate and water. The organic layer was washed with saturated aqueous sodium bicarbonate (50 mL x 2), brine (50 mL) then dried over sodium sulfate and concentrated *in vacuo*. The crude compound (2.0 g, 91% yield) was used directly in the next reaction with no further purification. HPLC Ret. Time: 2.56 min. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 2.30 (s, 3H), 3.90 (s, 3H), 5.26 (s, 1H), 7.18 (d, 1H), 7.49 (s, 1H), 7.52 (d, 1H).

Step 2: Compound B

To compound A (2.0 g, 12 mmol) in DMF (60 mL) at room temperature under argon was added sodium hydride (0.67 g, 17 mmol) in one portion. The reaction was stirred at room temp for 0.5h then dimethylthiocarbonyl chloride (2.1 g, 17 mmol) was added in one portion. The reaction was stirred at room temp for overnight. After quenching with water, the reaction mixture was extracted with ethyl acetate (100 mL x 4). The organic layer was washed with water (40 mL x 2), brine (50 mL) then dried over magnesium sulfate and concentrated *in vacuo*. The crude compound was purified by column chromatography to give 2.8 g (92 %) of a near white solid. HPLC Ret. Time: 2.90min. LCMS  $MH^+$  (m/z) 253.  $^1H$  NMR (400 MHz,  $CDCl_3$ ):  $\delta$  2.26 (s, 3H), 3.38 (s, 3H), 3.47 (s, 3H), 3.89 (s, 3H), 7.30 (d, 1H), 7.70 (s, 1H), 7.90 (d, 1H).

Step 3: Compound C


Compound B (4.3 g, 17 mmol) was heated under argon at 240°C for 4h. After cooling to room temp, 4.1 g (94 %) of brown viscous oil was obtained as the desired product. HPLC Ret. Time: 3.11min.  $^1H$  NMR (400 MHz,  $CDCl_3$ ):  $\delta$  2.46 (s, 3H), 3.02 (br. s, 3H), 3.14 (br. s, 3H), 3.88 (s, 3H), 7.37 (d, 1H), 7.97 (dd, 1H), 8.15 (d, 1H).

Step 4: Compound D

To Compound C (4.1 g, 16 mmol) in 3:1 methanol/water (60 mL) at 0°C was added lithium hydroxide monohydrate (0.68 g, 17 mmol) in one portion. After warming to room temp, the mixture was stirred for overnight. After the solvent was removed *in vacuo*, the mixture was diluted with water (50 mL) and extracted with diethyl ether (50 mL x 2).


The aqueous layer was brought to a pH of 1 with aqueous HCl and the resulting solid was collected by filtration to give 3.2 g (83 %) of a pale yellow solid. HPLC Ret. Time: 2.79min. LCMS  $MH^+$  (m/z) 240.  $^1H$  NMR (500 MHz,  $CDCl_3$ ):  $\delta$  2.48 (s, 3H), 3.03 (br. s, 3H), 3.15 (br. s, 3H), 7.40 (d, 1H), 8.01 (d, 1H), 8.20 (s, 1H).

Step 5: Compound E



To compound D (1.3 g, 5.7 mmol) in  $CH_2Cl_2$  (20 mL) cooled at  $-20^\circ C$  was added N-methyl morpholine (0.63 mL, 5.7 mmol) and isobutyl chloroformate (0.74 mL, 5.7 mmol) successively. The resulting mixture was stirred at  $-20^\circ C$  for 0.5h. At this time, a 2 M solution of ammonia in methanol (4.3 mL, 8.6 mmol) was added dropwise and followed by stirring at  $-20^\circ C$  for 1h and at room temp for 2h. Ethyl acetate (300 mL) was added and the organic layer was washed with water (50 mL x 2), 10% aqueous sodium carbonate (50 mL), and brine (50 mL), then the solution was dried over magnesium sulfate and concentrated *in vacuo*. The crude compound was triturated with 20% ethyl acetate in hexane and ether to give 0.77 g (56 %) of a near white solid as the pure product. HPLC Ret. Time: 2.20 min. LCMS  $MH^+$  (m/z) 239.  $^1H$  NMR (400 MHz,  $CDCl_3$ ):  $\delta$  2.46 (s, 3H), 3.03 (br. s, 3H), 3.14 (br. s, 3H), 5.5 (br. s, 1H), 6.1 (br. s, 1H), 7.38 (d, 1H), 7.77 (dd, 1H), 7.89 (d, 1H).


Step 6: Compound F



To Compound E (0.77 g, 3.2 mmol) in methanol (10 mL) at room temp was added 5 N aqueous sodium hydroxide solution (3.2 mL, 16 mmol) followed by refluxing for 1h. After the solvent was removed *in vacuo* the mixture was diluted with water (30 mL) and extracted with diethyl ether (50 mL x 2). The aqueous layer was brought to a pH of 1 with aqueous HCl and the resulting solid was collected by filtration to give 0.40 g (74 %) of a pale yellow solid. HPLC Ret. Time: 2.09 min. LCMS  $MH^+$  (m/z) 167.  $^1H$  NMR (400


MHz, CDCl<sub>3</sub>):  $\delta$  2.38 (s, 3H), 3.42 (s, 1H), 5.70 (br. s, 1H), 6.00 (br. s, 1H), 7.22 (d, 1H), 7.45 (dd, 1H), 7.77 (d, 1H).

#### Step 7: Compound G




To compound D (1.0 g, 4.2 mmol) in DMF (15 mL) was added 1-hydroxybenzotriazole (0.67 g, 5.0 mmol), 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (0.96 g, 5.0 mmol), *i*-Pr<sub>2</sub>NEt (2.2 mL, 12 mmol) and methylamine hydrochloride (0.34 g, 5.0 mmol) sequentially at room temp and the resulting mixture was stirred for overnight. Water was added followed by extraction with ethyl acetate. The organic extracts were successively washed with water, 1N aqueous HCl (50 mL x 2), water, saturated aqueous NaHCO<sub>3</sub>, and brine, then the solution was dried over magnesium sulfate. The solvent was removed *in vacuo* to give 0.89 g (84%) of a pale yellow solid. HPLC Ret. Time: 2.37min. LCMS MH<sup>+</sup> (m/z) 252. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>):  $\delta$  2.44 (s, 3H), 2.98 (d, 3H), 3.02 (br. s, 3H), 3.13 (br. s, 3H), 6.12 (br. s, 1H), 7.36 (d, 1H), 7.73 (dd, 1H), 7.82 (d, 1H).

#### Compound H




Compound H was prepared from compound D utilizing the same procedure as for compound E by substituting methoxyamine hydrochloride in place of methylamine HCl.


#### Compound I




Compound I was prepared from compound G utilizing the same procedure as for compound F.

Compound J


Compound J was prepared from compound H utilizing the same procedure as for compound F.

Compound K


To cyanuric chloride (0.20 g, 1.1 mmol) in DCM (2 mL) cooled in an ice bath was added a solution of *N*-methyl-neopentylamine hydrochloride (0.15 g, 1.1 mmol) and DIEA (0.60 mL, 3.5 mmol) in 1 mL of DCM dropwise. The resulting mixture was stirred at 0°C for 15 min and at room temp for 15 min, then cooled to 0°C. Compound I in DCM (2mL) was then added dropwise followed by stirring at 0°C for 15 min and at room temp for 2h. The resulting mixture was directly purified by column chromatography to give 0.36 g (86 %) of a white foam as the pure product. HPLC Ret. Time: 3.60 min. LCMS  $MH^+$  (m/z) 394.

Compound L

Compound L was prepared from compound K utilizing the same procedure as for compound K.

Compound M

Compound M was prepared from compound F utilizing the same procedure as for compound K.

Compound N

To compound K (25 mg, 0.07 mmol) in acetonitrile (0.2 mL) was added 1-methylhomopiperazine (11 mg, 0.1 mmol) and the resulting mixture was heated at 80°C for 2h. The pure product was isolated as an off-white solid following preparative HPLC. HPLC Ret. Time: 3.01min. LCMS  $MH^+$  ( $m/z$ ) 458.

Compounds O to S

Compounds O to S were prepared utilizing a similar procedure as for compound N except that compound L, compound M and 2-(aminomethyl)pyridine were substituted as starting materials when appropriate. See Table 2.

Compounds T to V


Compounds T to V were prepared utilizing a similar procedure as for compound N except that compound L, compound M and 3-(*R*)-*N*-tert-butoxycarbonyl pyrrolidine were substituted as starting materials when appropriate. In addition, the intermediates obtained from this procedure were subsequently exposed to 4 N HCl in dioxane at room temp for 1h



to cleave the BOC protecting group followed by concentration *in vacuo* to afford the corresponding HCl salts of the pure products. See Table 2

#### Preparation of Fluoro Anilines


##### Compound W




To 4-fluoro-3-nitrobenzoic acid (5.0 g, 27 mmol) in anhydrous dichloromethane (200 mL) at room temp was slowly added oxalyl chloride (12 mL, 0.14 mol) followed by 1 drop of DMF. The reaction was stirred at room temp for 2h then the solvent was removed *in vacuo* to afford the intermediate acid chloride as a yellow solid.

To a portion of the crude acid chloride (2.0 g, 9.9 mmol) in anhydrous dichloromethane (35 mL) was added triethylamine (4.1mL, 30 mmol) followed by methoxylamine hydrochloride (1.2 g, 15 mmol) and the resulting mixture was stirred at room temp for overnight. The reaction mixture was diluted with EtOAc and washed with water (50 mL x 2), saturated aqueous NaHCO<sub>3</sub> (50 mL x 2), brine (50 mL), then dried over magnesium sulfate, filtered, and concentrated *in vacuo*. The resulting residue was triturated with diethyl ether to give 1.3 g (60 %) of a light yellow solid as the pure product. HPLC Ret. Time: 1.57 min. <sup>1</sup>H NMR (400MHz, CDCl<sub>3</sub>): δ 3.86(s,3H), 7.35 (dd, 1H), 8.24 (ddd,1H), 8.65(dd, 1H), 11.75(s, 1H).


##### Compound X




Compound X was prepared utilizing a similar procedure as for compound W except that methoxylamine hydrochloride was substituted for the ammonia in methanol solution as a starting material.

Compound Y

To compound W (0.25 g) in absolute ethanol (20 mL) was added palladium on carbon (50 mg, 10%wt.) and hydrogenated under hydrogen (30 psi) for 3h. The solution was filtered through a bed of celite and the solvent was removed on *vacuo* to give 0.21 g light brown thick oil as the product. HPLC Ret. Time: 0.67min.  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  3.86 (br. s, 5H), 6.98 (dd, 1H), 7.00 (dd, 1H), 7.23 (dd, 1H), 8.63 (s, 1H).

Compound Z

Compound Z was prepared from compound X utilizing the same procedure as for compound Y.

Compounds A<sub>1</sub> and B<sub>1</sub>

Compounds A<sub>1</sub> and B<sub>1</sub> were prepared from compounds Y and Z utilizing a similar procedure as for compound K by substituting compound I with compounds Y and Z.

Compounds C<sub>1</sub> and D<sub>1</sub>

Compounds C<sub>1</sub> and D<sub>1</sub> were prepared from compounds A<sub>1</sub> and B<sub>1</sub> utilizing a similar procedure as used for compound N. See Table 3.

Compounds E<sub>1</sub> and F<sub>1</sub>


Compounds were prepared from compounds A<sub>1</sub> and B<sub>1</sub> utilizing a similar procedure as for compound N except that 3-(*R*)-amino-*N*-tertbutyloxycarbonyl pyrrolidine was used in place of *N*-methyl homopiperazine. In addition, the intermediates obtained from this procedure were subsequently exposed to 4 N HCl in dioxane at room temp for 1h

to cleave the BOC protecting group followed by concentration *in vacuo* to afford the corresponding HCl salts of the pure products. See Table 3.

Compounds wherein V is -O- may be prepared according to the following examples.

#### Preparation of Phenols


##### Compound G<sub>1</sub>



To a suspension of 3-hydroxy-4-methylbenzoic acid (2.5 g, 16 mmol) in 65 mL of DCM at room temp were successively added 5.7 mL of oxalyl chloride and 0.05 mL of DMF and the resulting mixture was stirred at room temp for 17h then concentrated *in vacuo* to afford the crude acid chloride intermediate as a viscous, pale yellow oil (~ 3 g).


Without further purification, the crude oil was dissolved in 30 mL of THF and one-half of this solution (15 mL) was slowly added to 16 mL of a 2 M solution of ammonia in methanol at 0°C. After warming to ambient temperature and stirring for 15h, the reaction mixture was concentrated *in vacuo* and the resulting residue was dissolved in 3 N aqueous KOH (50 mL) and washed with DCM (2x75 mL). The aqueous portion was carefully acidified using 6 N aqueous HCl to pH ~4, and the product was extracted with DCM (3 x 50 mL). The combined organic extracts were washed with brine (40 mL), dried over anhydrous sodium sulfate, filtered, and concentrated *in vacuo* to afford 0.90 g (72 %) of pure product as a light tan solid. <sup>1</sup>H NMR (400 MHz, d<sup>6</sup>-DMSO) : δ 9.44 (br s, 1H), 7.74 (br s, 1H), 7.27 (s, 1H), 7.21 (d, J = 7.6Hz, 1H), 7.13 (br s, 1H), 7.09 (d, J = 8.2Hz, 1H), 2.14 (s, 3H).

##### Compound H<sub>1</sub>




Compound H<sub>1</sub> was prepared using the same procedure as for compound G<sub>1</sub> except 4 mL of a 8M solution of methylamine in methanol was used in substitute for the 16 mL of a 2 M solution of ammonia in methanol. Compound H<sub>1</sub> was isolated as a light tan solid. <sup>1</sup>H NMR (400 MHz, d<sup>6</sup>-DMSO) : δ 9.46 (br s, 1H), 8.20 (br s, 1H), 7.25 (s, 1H), 7.16 (d, J = 7.6Hz, 1H), 7.10 (d, J = 8.1Hz, 1H), 2.74 (d, J = 4.6Hz, 3H), 2.14 (s, 3H).

Compound I<sub>1</sub>



A mixture of 3-hydroxy-4-methylbenzoic acid (2.0 g, 13 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (3.3 g, 17 mmol), HOBt (2.1 g, 16 mmol), DIEA (7.2 mL, 53 mmol) and methoxylamine hydrochloride (1.3 g, 16 mmol) in 30 mL of DMF was stirred at room temp for 3 days. The resulting mixture was poured into 350 mL of water and was extracted with ethyl acetate (4 x 100 mL). The combined extracts were washed with saturated aqueous sodium bicarbonate (3 x 75 mL), water (3 x 75 mL), and brine (2 x 100 mL), then dried over anhydrous sodium sulfate. The solution was filtered and concentrated *in vacuo* and the resulting yellow solid was dissolved in ~30 mL of 1 N aqueous sodium hydroxide and washed with DCM (2 x 20 mL). The aqueous portion was then acidified using 3 N aqueous HCl to pH ~ 4 and the aqueous solution was extracted with ethyl acetate (3 x 30 mL). The combined organic extracts were dried over anhydrous sodium sulfate, filtered, and concentrated *in vacuo* to afford 0.47 g (20 %) of the pure product as an off-white solid. <sup>1</sup>H NMR (400 MHz, d<sup>6</sup>-DMSO) : δ 11.54 (s, 1H), 9.59 (s, 1H), 7.18 (s, 1H), 7.12 (d, J = 7.7Hz, 1H), 7.05 (d, J = 7.7Hz, 1H), 3.67 (s, 3H), 2.14 (s, 3H).

Compound J<sub>1</sub>



To a 0°C solution of cyanuric chloride (0.20 g, 1.1 mmol) in DCM was slowly added dropwise a solution of compound A (0.17 g, 1.1 mmol) and DIEA (0.23 mL, 1.3 mmol) in 1 mL of DMF. After stirring at 0°C for 15 min, a solution of *N*-methylneopentylamine hydrochloride (0.16 g, 1.1 mmol) and DIEA (0.62 mL, 3.5 mmol) in 1 mL of DCM was slowly added dropwise at 0°C. The resulting mixture was stirred at 0°C for 1h, then 4 mL of 1 N aqueous HCl was slowly added followed by dilution of the reaction mixture with 30 mL of methylene chloride. The layers were separated, and the organic layer was washed with additional 1 N aqueous HCl (2 x 15 mL), water (15 mL), and brine (15 mL), then the solution was dried over anhydrous sodium sulfate, filtered, and concentrated *in vacuo* to afford 0.4 g of a pale yellow oil as the crude monochloride intermediate.

The crude oil was dissolved in 0.9 mL of DMF, and to one-third (~ 0.3 mL) of the resulting solution was added *N*-methylhomopiperazine (56 mg, 0.50 mmol) and DIEA (30  $\mu$ L, 1.7 mmol). The mixture was heated to 85°C for 3h followed by cooling to room temp. Pure compound D was obtained by preparative HPLC of the reaction mixture to afford 83 mg (92 %) of the corresponding TFA salt of the pure product as a white solid. HPLC Ret. Time: 2.66 min. LCMS  $MH^+$  ( $m/z$ ) 442.

#### Compounds K<sub>1</sub> to O<sub>1</sub>

Compounds K<sub>1</sub> to O<sub>1</sub> were prepared using the same procedure as for compound J<sub>1</sub> except that compound H, compound I and 2-(aminomethyl)pyridine were used as starting materials when appropriate. Pure final compounds were obtained by preparative HPLC of the reaction mixture to afford the pure products as their trifluoroacetic acid salts. See Table 4.


#### Compounds P<sub>1</sub> to R<sub>1</sub>

Compounds P to R were prepared using the same procedure as for compound J except that compound H or compound I, and 3-(*R*)-amino-N-(tert-butoxycarbonyl)pyrrolidine were used as starting materials when appropriate. In addition, the intermediates obtained from this procedure were subsequently exposed to 4 N HCl in dioxane at room temp for 1h to cleave the BOC protecting group followed by concentration *in vacuo* to afford the corresponding HCl salts of the pure products. See Table 4.

HPLC retention times were determined using a YMC S5 ODS 4.6 mm x 50 mm Ballistic chromatography column with a 4 min total gradient elution time and a flow rate of 4 mL/min. The elution gradient uses 100% of solvent A and gradually increases to 100% of solvent B over the 4 min elution time (solvent A = 10% methanol / 90% water / 0.2% phosphoric acid and solvent B = 90% methanol / 10% water 0.2% phosphoric acid). Eluted products were detected using a UV detector at a wavelength of 220 nm.


#### Custom Synthon Synthesis

##### 4-Benzyloxy-2-hydroxymethyl-pyrrolidine-1-carboxylic acid *t*-butyl ester




The 4-benzyloxy-pyrrolidine-1,2-dicarboxylic acid 1-*t*-butyl ester (1.00 g, 3.11 mmol) was taken up in anhydrous THF under argon and cooled to 0°C. BH<sub>3</sub>·THF (1.0 M, 6.22 mmol, 6.22 mL) was added to the solution dropwise over 10 min. The reaction mixture was then allowed to stir at 0°C for 30 min then warmed to room temp and stirred for an additional 30 min. The reaction was slowly poured into a 1N HCl solution and the aqueous layer was extracted three times with ethyl acetate. The combined organic layers were washed with water and brine then dried over MgSO<sub>4</sub>. The solution was filtered and the solvent removed under reduced pressure. The product was isolated by flash chromatography. (1:1 hexane-ethyl acetate) Yield 814 mg. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 1.48 (s, 9H), 1.63-1.76 (m, 1H), 2.10-2.26 (m, 1H), 3.33 (m, 1H), 3.50-3.60 (m, 1H), 3.63-3.75 (m, 2H), 4.05-4.19 (m, 2H), 4.49 (s, 2H), 7.23-7.39 (m, 5H).

4-Benzyloxy-2-methoxymethyl-pyrrolidine-1-carboxylic acid *t*-butyl ester




The alcohol (250 mg, 0.81 mmol) and methyl iodide (344.91 mg, 2.43 mmol, 0.15 mL) were dissolved in anhydrous THF under argon. Solid NaH (29.28 mg, 1.22 mmol) was slowly added to the solution under argon. The reaction was then stirred for 12h at room temp. The reaction was slowly poured into a 1N HCl solution and the aqueous layer was extracted three times with ethyl acetate. The combined organic layers were washed with water and brine then dried over MgSO<sub>4</sub>. The solution was filtered and the solvent removed under reduced pressure. The product was isolated by flash chromatography. (4:1 hexane-ethyl acetate) Yield 217 mg. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 1.27 (s, 9H), 2.06-2.16 (m, 2H), 3.32 (s, 3H), 3.40-3.52 (m, 3H), 4.09-4.21 (m, 1H), 2.49 (s, 2H), 7.23-7.36 (m, 5H).


4-Hydroxy-2-methoxymethyl-pyrrolidine-1-carboxylic acid *t*-butyl ester



The benzyloxy-2-methoxymethyl-pyrrolidine-1-carboxylic acid *t*-butyl ester (217.00 mg, 0.68 mmol) was taken up in ethyl acetate in a Paar vessel. The solution was flushed with argon and Pd/C (100 mg) was added to the vessel. The argon atmosphere was replaced by hydrogen at 50 psi. The vessel was shaken for 12h. The hydrogen atmosphere was replaced by argon and the solution was filtered through a celite pad. The pad was washed twice with ethyl acetate. The solvent was removed under reduced pressure. The product was used without further purification. Yield 148.35 mg. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 1.42 (s, 9H), 1.80-2.10 (m, 2H), 3.05 (bs, 1H), 3.30 (s, 3H), 3.34-3.50 (m, 3H), 4.00 (bs, 1H), 4.33-4.40 (m, 1H).

4-Methanesulfonyloxy-2-methoxymethyl-pyrrolidine-1-carboxylic acid *t*-butyl ester

The 4-hydroxy-2-methoxymethyl-pyrrolidine-1-carboxylic acid *t*-butyl ester (148.35 mg, 0.64 mmol) was dissolved in anhydrous DCM and triethylamine (194.28 mg, 1.92 mmol, 0.27 mL) was added under argon. The reaction mixture was cooled to 0°C and methanesulfonyl chloride (80.64 mg, 0.70 mmol, 0.06 mL) was added via syringe. The reaction was stirred at 0°C for 30 min and then allowed to warm to room temp and stir for 12h. The reaction was slowly poured into a 1N HCl solution and the aqueous layer was extracted three times with ethyl acetate. The combined organic layers were washed with water and brine then dried over MgSO<sub>4</sub>. The solution was filtered and the solvent removed under reduced pressure. The product was isolated by flash chromatography. (2:1 hexane-ethyl acetate) Yield 172.26 mg. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) : δ 1.49 (s, 9H), 2.32 (bs, 2H), 3.04 (s, 3H), 3.35 (s, 3H), 3.44 (d, J = 6Hz, 1H), 3.49-3.88 (m, 3H), 4.11 (bs, 1H), 5.25 (m, 1H).


4-Azido-2-methoxymethyl-pyrrolidine-1-carboxylic acid *t*-butyl ester

The 4-methanesulfonyloxy-2-methoxymethyl-pyrrolidine-1-carboxylic acid *t*-butyl ester (172.26 mg, 0.56 mmol) was taken up in dry DMF under argon and sodium azide (182.00 mg, 2.80 mmol) was added. The reaction was then heated to 60°C for 48h. The reaction was poured into water and the aqueous layer was extracted three times with ethyl acetate. The combined organic layers were washed with sat NaHCO<sub>3</sub> and brine then dried over MgSO<sub>4</sub>. The solution was filtered and the solvent removed under reduced pressure. The




product was isolated by flash chromatography. (3:1 hexane-ethyl acetate) Yield 122.00 mg.  
 $C_{11}H_{22}N_2O_3$  MS  $m/e = 257.3$  (M+H).

4-Amino-2-methoxymethyl-pyrrolidine-1-carboxylic acid *t*-butyl ester



The 4-azido-2-methoxymethyl-pyrrolidine-1-carboxylic acid *t*-butyl ester (122.00 mg, 0.48 mmol) was taken up in ethyl acetate in a Paar vessel. The solution was flushed with argon and Pd/C (100.00 mg) was added to the vessel. The argon atmosphere was replaced by hydrogen at 50 psi. The vessel was shaken for 12h. The hydrogen atmosphere was replaced by argon and the solution was filtered through a celite pad. The pad was washed twice with ethyl acetate. The solvent was removed under reduced pressure. The product was used without further purification. Yield 99.76 mg.  
 $C_{11}H_{22}N_2O_3$  MS  $m/e/230.2$  ( $M^+$ ).

4-Benzoyloxy-2-(*t*-butyl-dimethyl-silanyloxymethyl)-pyrrolidine-1-carboxylic acid *t*-butyl ester




The 4-benzyloxy-2-hydroxymethyl-pyrrolidine-1-carboxylic acid *t*-butyl ester (250 mg, 0.81 mmol) was taken up in dry DMF under argon and imidazole (110.29 mg, 1.62 mmol) was added. *T*-butyldimethylsilylchloride (134.29 mg, 0.89 mmol) was added and the solution was stirred at room temp for 12h. The reaction was slowly poured into a 1N HCl solution and the aqueous layer was extracted three times with ethyl acetate. The combined organic layers were washed with water and brine then dried over  $MgSO_4$ . The solution was filtered and the solvent removed under reduced pressure. The product was isolated by flash chromatography. (5:1 hexane-ethyl acetate) Yield 267.49 mg.  $^1H$  NMR ( $CDCl_3$ , 300 MHz):  $\delta$  0.02 (m, 6 h), 0.83 (s, 9H), 1.25 (s, 9H), 1.98-2.13 (m, 1H), 2.13-2.24 (m, 1H), 3.36-3.70

(m, 3H), 3.86-3.95 (m, 1H), 4.00 (bs, 1H), 4.15-4.28 (m, 1H), 4.50 (bs, 2H), 7.23-7.37 (m, 5H).


2-(*t*-Butyl-dimethyl-silanyloxymethyl)-4-hydroxy-pyrrolidine-1-carboxylic acid

*t*-butyl ester



The 4-benzyloxy-2-(*t*-butyl-dimethyl-silanyloxymethyl)-pyrrolidine-1-carboxylic acid *t*-butyl ester (267.49 mg, 0.63 mmol) was taken up in ethyl acetate in a Paar vessel. The solution was flushed with argon and Pd/C (100 mg) was added to the vessel. The argon atmosphere was replaced by hydrogen at 50 psi. The vessel was shaken for 12h. The hydrogen atmosphere was replaced by argon and the solution was filtered through a celite pad. The pad was washed twice with ethyl acetate. The solvent was removed under reduced pressure. The product was used without further purification. Yield 192.15 mg.  $C_{16}H_{33}NO_4Si$  ms  $m/e = 3.32.2$  (M+H).


2-(*t*-Butyl-dimethyl-silanyloxymethyl)-4-methane sulfonyloxy-pyrrolidine-1-carboxylic acid *t*-butyl ester



The 4-hydroxy-2-(*t*-butyl-dimethyl-silanyloxymethyl)-pyrrolidine-1-carboxylic acid *t*-butyl ester (192.15 mg, 0.58 mmol) was dissolved in anhydrous DCM and triethylamine (176.07 mg, 1.74 mmol, 0.24 mL) was added under argon. The reaction mixture was cooled to 0°C and methanesulfonyl chloride (73.08 mg, 0.64 mmol, 0.05 mL) was added via syringe. The reaction was stirred at 0°C for 30 min and then allowed to warm to room temp and stir for 12h. The reaction was slowly poured into a 1N HCl solution and the aqueous layer was extracted three times with ethyl acetate. The combined organic layers were washed with water and brine then dried over  $MgSO_4$ . The solution was filtered and the solvent removed under reduced pressure. The product was isolated by flash chromatography. (4:1 hexane-


ethyl acetate) Yield 220.94 mg.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz) :  $\delta$  0.05 (m, 6H), 0.89 (s, 9H), 1.46 (s, 9H), 2.20-2.43 (m, 2H), 3.04 (s, 3H), 3.48-3.92 (m, 4H), 3.93-4.10 (m, 1H), 5.31 (bs, 1H).

4-Azido-2-(*t*-butyl-dimethyl-silanyloxymethyl)-pyrrolidine-1-carboxylic acid *t*-butyl ester




The 4-methanesulfonyloxy-2-(*t*-butyl-dimethyl-silanyloxymethyl)-pyrrolidine-1-carboxylic acid *t*-butyl ester (220.94 mg, 0.54 mmol) was taken up in dry DMF under argon and sodium azide (175.31 mg, 2.70 mmol) was added. The reaction was then heated to 60°C for 48h. The reaction was poured into water and the aqueous layer was extracted three times with ethyl acetate. The combined organic layers were washed with sat  $\text{NaHCO}_3$  and brine then dried over  $\text{MgSO}_4$ . The solution was filtered and the solvent removed under reduced pressure. The product was isolated by flash chromatography. (5:1 hexane-ethyl acetate) Yield 184.83 mg.  $\text{C}_{16}\text{H}_{32}\text{N}_4\text{O}_3\text{Si}$  MS  $m/e = 357.3$  ( $\text{M}+\text{H}$ ).


4-Amino-2-(*t*-butyl-dimethyl-silanyloxymethyl)-pyrrolidine-1-carboxylic acid *t*-butyl ester



The 4-azido-2-(*t*-butyl-dimethyl-silanyloxymethyl)-pyrrolidine-1-carboxylic acid *t*-butyl ester (184.83 mg, 0.52 mmol) was taken up in ethyl acetate in a Paar vessel. The solution was flushed with argon and Pd/C (150 mg) was added to the vessel. The argon atmosphere was replaced by hydrogen at 50 psi. The vessel was shaken for 12h. The hydrogen atmosphere was replaced by argon and the solution was filtered through a celite pad. The pad was washed twice with ethyl acetate. The solvent was removed under reduced pressure. The product was used without further purification. Yield 154.69 mg.  $\text{C}_{16}\text{H}_{34}\text{N}_2\text{O}_3\text{Si}$  MS  $m/e = 331.2$  ( $\text{M}+\text{H}$ ).

4-Benzoyloxy-2-methanesulfonyloxymethyl-pyrrolidine-1-carboxylic acid *t*-butyl ester


The 4-benzyloxy-2-hydroxymethyl-pyrrolidine-1-carboxylic acid *t*-butyl ester (219.09 mg, 0.71 mmol) was taken up in anhydrous DCM and triethylamine (215.53 mg, 2.13 mmol, 0.30 mL) was added under argon. The reaction mixture was cooled to 0°C and methanesulfonyl chloride (89.81 mg, 0.78 mmol, 0.06 mL) was added via syringe. The reaction was stirred at 0°C for 30 min and then allowed to warm to room temp and stir for 12h. The reaction was slowly poured into a 1N HCl solution and the aqueous layer was extracted three times with ethyl acetate. The combined organic layers were washed with water and brine then dried over MgSO<sub>4</sub>. The solution was filtered and the solvent removed under reduced pressure. The product was isolated by flash chromatography. (3:1 hexane-ethyl acetate) Yield 234.14 mg. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) : δ 1.47 (bs, 9H), 2.05-2.32 (m, 2H), 2.98 (s, 3H), 3.31-3.63 (m, 2H), 4.04-4.78 (m, 6H), 7.27-7.40 (m, 5H).

4-Hydroxy-2-methoxymethyl -pyrrolidine-1-carboxylic acid *t*-butyl ester

The 4-benzyloxy-2-methanesulfonyloxymethyl-pyrrolidine-1-carboxylic acid *t*-butyl ester (234.14 mg, 0.65 mmol) was taken up in anhydrous THF under argon and cooled to 0°C. Super-Hydride (1.0M, 0.98 mmol, 0.98 mL) was added via a syringe over 10 min. The solution was stirred for 1 h at 0°C, the TLC indicated that no starting material remained. The reaction mixture was slowly poured into a 1N HCl solution and the aqueous layer was extracted three times with ethyl acetate. The combined organic layers were washed with water and brine then dried over MgSO<sub>4</sub>. The solution was filtered and the solvent removed


under reduced pressure. The product was isolated by flash chromatography. (4:1 hexane-ethyl acetate) Yield 168.57 mg.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz) :  $\delta$  1.22 (d,  $J = 9.0\text{Hz}$ , 3H), 1.44 (s, 9H), 1.65-1.77 (m, 1H), 2.13-2.24 (m, 1H), 3.45 (dd,  $J = 7, 12\text{Hz}$ , 1H), 3.61 (d,  $J = 7\text{Hz}$ , 1H), 3.94-4.04 (m, 1H), 4.50 (s, 2H), 7.27-7.39 (m, 5H).

4-Hydroxy-2-methyl-pyrrolidine-1-carboxylic acid *t*-butyl ester



The 4-benzyloxy-2-methyl-pyrrolidine-1-carboxylic acid *t*-butyl ester (168.57 mg, 0.58 mmol) was taken up in ethyl acetate in a Paar vessel. The solution was flushed with argon and Pd/C (100.00 mg) was added to the vessel. The argon atmosphere was replaced by hydrogen at 50 psi. The vessel was shaken for 12h. The hydrogen atmosphere was replaced by argon and the solution was filtered through a celite pad. The pad was washed twice with ethyl acetate. The solvent was removed under reduced pressure. The product was used without further purification. Yield 110.89 mg.  $\text{C}_{10}\text{H}_{19}\text{NO}_3$  MS  $m/e=202.1(\text{M}+\text{H})$ .


4-Methanesulfonyloxy-2-methyl-pyrrolidine-1-carboxylic acid *t*-butyl ester



The 4-hydroxy-2-methyl-pyrrolidine-1-carboxylic acid *t*-butyl ester (110.89 mg, 0.55 mmol) was dissolved in anhydrous DCM and triethylamine (166.96 mg, 1.65 mmol, 0.23 mL) was added under argon. The reaction mixture was cooled to  $0^\circ\text{C}$  and methanesulfonyl chloride (69.30 mg, 0.61 mmol, 0.05 mL) was added via syringe. The reaction was stirred at  $0^\circ\text{C}$  for 30 min and then allowed to warm to room temp and stir for 12h. The reaction was slowly poured into a 1N HCl solution and the aqueous layer was extracted three times with ethyl acetate. The combined organic layers were washed with water and brine then dried over  $\text{MgSO}_4$ . The solution was filtered and the solvent removed under reduced pressure. The product was isolated by flash chromatography. (3:1 hexane-ethyl acetate) Yield 135.21 mg.

$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz) :  $\delta$  1.27 (d,  $J=9\text{Hz}$ , 3H), 1.48 (s, 9H), 1.81-1.92 (m, 1H), 2.43 (bs, 1H), 3.04 (s, 3H), 3.56 (dd,  $J = 7.17\text{Hz}$ , 1H), 3.84 (bs, 1H), 4.01 (bs, 1H), 5.17 (bs, 1H).


4-Azido-2-methyl-pyrrolidine-1-carboxylic acid *t*-butyl ester




The 4-methanesulfonyloxy-2-methyl-pyrrolidine-1-carboxylic acid *t*-butyl ester (135.21 mg, 0.48 mmol) was taken up in dry DMF under argon and sodium azide (156.00 mg, 2.40 mmol) was added. The reaction was then heated to  $60^\circ\text{C}$  for 48h. The reaction was poured into water and the aqueous layer was extracted three times with ethyl acetate. The combined organic layers were washed with sat  $\text{NaHCO}_3$  and brine then dried over  $\text{MgSO}_4$ . The solution was filtered and the solvent removed under reduced pressure. The product was isolated by flash chromatography. (5:1 hexane-ethyl acetate) Yield 93.41 mg.

$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz) :  $\delta$  1.32 (d,  $J = 9\text{Hz}$ , 3H), 1.47 (s, 3H), 1.72 (dt,  $J = 2$ , 12Hz, 1H), 2.28-2.37 (m, 1H), 3.34 (dd,  $J = 7$ , 12Hz, 1H), 3.63-3.72 (m, 1H), 3.93 (bs, 1H), 4.05-4.14 (m, 1H).


4-Amino-2-methyl-pyrrolidine-1-carboxylic acid *t*-butyl ester




The 4-azido-2-methyl-pyrrolidine-1-carboxylic acid *t*-butyl ester (93.41 mg, 0.41 mmol) was taken up in ethyl acetate in a Paar vessel. The solution was flushed with argon and Pd/C (100.00 mg) was added to the vessel. The argon atmosphere was replaced by hydrogen at 50 psi. The vessel was shaken for 12h. The hydrogen atmosphere was replaced by argon and the solution was filtered through a celite pad. The pad was washed twice with ethyl acetate. The solvent was removed under reduced pressure. The product was used without further purification. Yield 79.65 mg.  $\text{C}_{10}\text{H}_{20}\text{N}_2\text{O}_2$  MS  $m/e = 200.2$  ( $\text{M}^+$ ).

2-Methyl-4-(4-nitro-benzoyloxy)-pyrrolidine-1-carboxylic acid *t*-butyl ester


The 4-hydroxy-2-methyl-pyrrolidine-1-carboxylic acid *t*-butyl ester (300.00 mg, 1.49 mmol) and triphenyl phosphine (512.54, 1.95 mmol) were dissolved in anhydrous THF and added to a mixture of para-nitrobenzoic acid (249.00 mg, 1.49 mmol) and DEAD (268.00 mg, 1.54 mmol, 0.24 mL) in anhydrous THF at 0°C under argon. The mixture was stirred for 1 h at 0°C. After 1 h the TLC indicated no starting material remained and the reaction mixture was poured into a 1N HCl solution and the aqueous layer was extracted three times with ethyl acetate. The combined organic layers were washed with water and brine then dried over MgSO<sub>4</sub>. The solution was filtered and the solvent removed under reduced pressure. The product was isolated by flash chromatography. (2:1 hexane-ethyl acetate) Yield 391.54 mg. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 1.39 (d, J = 9Hz, 3H), 1.49 (s, 9H), 1.99 (d, J = 15Hz, 1H), 2.24-2.33 (m, 1H), 3.62-3.71 (m, 1H), 3.82 (dd, J = 7, 12Hz, 1H), 4.13 (bs, 1H), 5.52-5.56 (m, 1H), 8.20-8.35 (m, A<sub>2</sub>B<sub>2</sub>), 4H).

4-Hydroxy-2-methyl-pyrrolidine-1-carboxylic acid *t*-butyl ester

The 4-hydroxy-2-methyl-pyrrolidine-1-carboxylic acid *t*-butyl ester (391.54 mg, 1.12 mmol) was dissolved in a 4:1 mixture of THF-water and LiOH (5.59 mmol) was added. The mixture was stirred for 12 h at room temp. The reaction mixture was poured into a 1N HCl solution and the aqueous layer was extracted three times with ethyl acetate. The combined organic layers were washed with water and brine then dried over MgSO<sub>4</sub>. The solution was filtered and the solvent removed under reduced pressure. The product was isolated by flash chromatography. (2:1 hexane-ethyl acetate) Yield 220.90 mg. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 1.35 (d, J = 9Hz, 3H), 1.46 (s, 9H), 1.67 (dt, J = 2, 15Hz, 1H), 3.38 (bs, 1H), 3.60 (dd, J = 7, 17Hz, 1H), 3.84-3.97 (m, 1H), 4.34-4.42 (m, 1H).


4-Amino-2-methyl-pyrrolidine-1-carboxylic acid *t*-butyl ester

The *R*-isomer was prepared by the proceeding experimental procedures. Yield 163.99 mg

4-Hydroxy-pyrrolidine-1,2-dicarboxylic acid 1-*t*-butyl ester 2-methyl ester

4-Benzyloxy-pyrrolidine-1,2-dicarboxylic acid 1-*t*-butyl ester 2-methyl ester (500 mg, 1.49 mmol) was taken up in ethyl acetate in a Paar vessel. The solution was flushed with argon and Pd/C (200 mg) was added to the vessel. The argon atmosphere was replaced by hydrogen at 50 psi. The vessel was shaken for 12h. The hydrogen atmosphere was replaced by argon and the solution was filtered through a celite pad. The pad was washed twice with ethyl acetate. The solvent was removed under reduced pressure. The product was used without further purification. Yield 350.98 mg.

$C_{11}H_{19}NO_5$  MS  $m/e = 246.2$  (M+H).


4-Methanesulfonyloxy-pyrrolidine-1,2-dicarboxylic acid 1-*t*-butyl ester 2-methyl ester

4-Hydroxy-pyrrolidine-1,2-dicarboxylic acid 1-*t*-butyl ester 2-methyl ester (350.98 mg, 1.43 mmol) was dissolved in anhydrous DCM and triethylamine (434.11 mg, 4.29 mmol, 0.6 mL) was added under argon. The reaction mixture was cooled to 0°C and methanesulfonyl chloride (180.19 mg, 1.57 mmol, 0.12 mL) was added via syringe. The reaction was stirred at 0°C for 30 min and then allowed to warm to room temp and stir for 12h. The reaction was slowly poured into a 1N HCl solution and the aqueous layer was extracted three times with ethyl acetate. The combined organic layers were washed with




water and brine then dried over  $\text{MgSO}_4$ . The solution was filtered and the solvent removed under reduced pressure. The product was isolated by flash chromatography. (2:1 hexane-ethyl acetate) Yield 406.92 mg.  $\text{C}_{12}\text{H}_{21}\text{NO}_7\text{S}$  MS  $m/e = 323.1$  (M+H).

4-Azido-pyrrolidine-1,2-dicarboxylic acid 1-*t*-butyl ester 2-methyl ester




4-Methanesulfonyloxy-pyrrolidine-1,2-dicarboxylic acid 1-*t*-butyl ester 2-methyl ester (406.92 mg, 1.26 mmol) was taken up in dry DMF under argon and sodium azide (409.50 mg, 6.30 mmol) was added. The reaction was then heated to 60°C for 48h. The reaction was poured into water and the aqueous layer was extracted three times with ethyl acetate. The combined organic layers were washed with sat  $\text{NaHCO}_3$  and brine then dried over  $\text{MgSO}_4$ . The solution was filtered and the solvent removed under reduced pressure. The product was isolated by flash chromatography. (3:1 hexane-ethyl acetate) Yield 303.10 mg.  $\text{C}_{11}\text{H}_{18}\text{N}_4\text{O}_4$  MS  $m/e = 271.2$  (M+H).

4-Amino-pyrrolidine-1,2-dicarboxylic acid 1-*t*-butyl ester 2-methyl ester



4-Azido-pyrrolidine-1,2-dicarboxylic acid 1-*t*-butyl ester 2-methyl ester (303.10 mg, 1.12 mmol) was taken up in ethyl acetate in a Paar vessel. The solution was flushed with argon and Pd/C (400.00 mg) was added to the vessel. The argon atmosphere was replaced by hydrogen at 50 psi. The vessel was shaken for 12h. The hydrogen atmosphere was replaced by argon and the solution was filtered through a celite pad. The pad was washed twice with ethyl acetate. The solvent was removed under reduced pressure. The product was used without further purification. Yield 262.66 mg.  $\text{C}_{11}\text{H}_{20}\text{N}_2\text{O}_4$  MS  $m/e = 244.2$  (M+).

(3*R*)-3-Aminopyrrolidine-1-carboxylic acid *t*-butyl ester




To a solution of (3R)-(+)-3-aminopyrrolidine (5.0 g, 58.0 mmol) in DCM (100 mL), benzophenone imine (10.52 g, 58.0 mmol) was added at room temp. The mixture was stirred for 18h. Imine was obtained by removal of the solvent under reduced pressure.

DCM (120 mL) and DIEA (20.0 mL, 115.1 mmol) were added to the imine, and di-*t*-butyl dicarbonate (14.0 g, 63.8 mmol) was then added to the solution in portions. The reaction was stirred for 4h at room temp. The mixture was poured into brine and extracted with DCM (3x40 mL). The combined organic phase was dried over Na<sub>2</sub>SO<sub>4</sub> and then concentrated. The residue was purified by silica gel chromatography (first with 10% ethyl acetate-hexane, and then 20% ethyl acetate-hexane as eluent). The Boc-amine was obtained as white solid. (12.89 g, 63%). MS (m/z) calcd for C<sub>22</sub>H<sub>26</sub>N<sub>2</sub>O<sub>2</sub> (MH<sup>+</sup>), 351; found, 351.

To the methanol solution (100 mL) of Boc-amine at 0°C, 0.4 M HCl (110.0 mL, 44.2 mmol) was added, and the resulting solution was stirred for 2h at 0°C. The mixture was poured into water and washed with DCM (3x40 mL). 6N NaOH was added to adjust the aqueous phase to pH 10, and the product was extracted with ethyl acetate (3x40 mL). The organic layer was dried over Na<sub>2</sub>SO<sub>4</sub>, and subsequent concentration yielded the product, (3R)-3-amino-pyrrolidine-1-carboxylic acid *t*-butyl ester as white solid (6.0 g, 88%). MS (m/z) calcd for C<sub>9</sub>H<sub>18</sub>N<sub>2</sub>O<sub>2</sub> (MH<sup>+</sup>), 187; found, 187.


(2,2-Dimethyl-propyl)-ethyl-amine



A solution of neopentylamine (2.0 g, 23.0 mmol), acetyl chloride (1.96 mL, 27.6 mmol), triethylamine (3.84 mL, 27.5 mmol), and DCM (100 mL) were stirred at room temp for 2h. The mixture was poured into water and extracted with DCM (3x40 mL). The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, and the solvent was removed to afford *N*-neopentylacetamide as white solid (2.90 g, 98%). NMR confirmed the structure of *N*-neopentylacetamide.

To a THF (100 mL) solution of *N*-neopentylacetamide (2.90 g, 22.5 mmol), 1M LiAlH<sub>4</sub> (28 mL, 28.0 mmol) in THF was added dropwise at room temp, and the reaction was stirred for 18h at 70°C. After cooling, 1N NaOH (28.0 mL) was added dropwise to the solution. The mixture was stirred for 15 min, and the white suspension solution was filtered through celite. 1M HCl in dioxane (10 mL) was added to the solution, and the mixture was stirred for 15 min. The solvent was removed to afford (2,-dimethyl-propyl)-ethyl-amine as HCl salt (3.10 g, 89%). MS (m/z) calcd for C<sub>7</sub>H<sub>17</sub>N (MH<sup>+</sup>), 116; found, 231 (dimer).

Methyl-(1-methyl-cyclopentylmethyl)-amine




To a THF solution (5 mL) of cyclopentanecarbonitrile (4.39 mL, 42.0 mmol), 2M NaHMDS (25.0 mL, 50.0 mmol) in THF was added dropwise under argon at 0°C. The reaction was stirred for 15 min and methyl iodide (3.14 mL, 50.4 mmol) was then added dropwise to the solution at 0°C. The reaction was stirred for 2h at 0°C, and 1M BH<sub>3</sub> (126 mL, 126 mmol) in THF was added to the mixture at room temp. The mixture was stirred for 3h, and 6N HCl was added dropwise to the mixture at 0°C until pH reached 2. The mixture was stirred for 15 min. The mixture was poured into water and washed with DCM (3x40mL). NaOH was added to the aqueous phase to adjust the pH to 11. (1-methyl-dicyclopentylmethyl)-amine was extracted with ethyl acetate (3x40 mL). The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>. The solvent was removed to afford (1-methyl-cyclopentylmethyl)-amine as yellow oil (2.0 g, 44%). MS (m/z) calcd for C<sub>7</sub>H<sub>15</sub>N (MH<sup>+</sup>), 114; found, 227 (dimer), 340 (trimer).

A solution of (1-methyl-cyclopentylmethyl)-amine (1.5 g, 13.3 mmol), ethyl chloroformate (1.52 mL, 16 mmol), and *N,N*-DIEA (2.79 mL, 16.0 mmol) in DCM (50 mL) was stirred at room temp for 18h. The mixture was poured into water and extracted with DCM (3x40 mL). The organic phase was dried over Na<sub>2</sub>SO<sub>4</sub>, and the solvent was removed to

afford (1-methyl-cyclopentylmethyl)-carbamic acid ethyl ester as colorless oil (1.62 g, 66%). MS (m/z) calcd for  $C_{10}H_{19}NO_2$  ( $MH^+$ ), 186; found 186.

To a THF solution (15 mL) of (1-methyl-cyclopentylmethyl)-carbamic acid ethyl ester (0.84 g, 4.54 mmol), 1M  $LiAlH_4$  (5.45 mL, 5.45 mmol) in THF was added dropwise at room temp. The reaction was stirred for 18h at 70°C. After cooling, 1N, NaOH (5.45 mL) was added dropwise to the solution. The mixture was stirred for 15 min. The white suspension was filtered through celite. 1M HCl (3 mL) in dioxane was added to the solution. The mixture was stirred for 15 min. The solvent was removed to afford methyl-(1-methyl-cyclopentylmethyl)-amine as HCl salt (380 mg, 51%). MS (m/z) calcd for  $C_8H_{17}N$  ( $MH^+$ ), 128; found, 128; found 128, 255 (dimer).


#### 3-Amino-N-ethyl-4-methyl-benzamide



4-methyl-3-nitro-benzoyl chloride (1.0 g, 5.0 mmol) was dissolved in DCM, and the solution was cooled to 0°C. Ethyl amine (2.0M in THF, 5.0 mL, 10 mmol) was added dropwise to the acid chloride, and the reaction stirred at 0°C for 5 min. The ice bath was removed and reaction continued to stir for 3. The solution was washed with brine, dried ( $Na_2SO_4$ ), and concentrated *in vacuo*. The resulting aniline (0.75 g) was used without further purification.

#### Coupling of Cyanuric Chloride with Aminobenzamide


##### 1. 3-Chloro-5-(4,6-dichloro-[1,3,5]triazin-2-ylamino)-4-methyl-benzamide



Cyanuric chloride (65.0 mg, 0.35 mmol) was added to an acetone solution (5 mL) of 3-amino-5-chloro-4-methyl-benzamide (65.0 mg, 0.35 mmol) at 0°C. The mixture was stirred for 1h at 0°C. Ice was added to the mixture and subsequent filtration yielded of 3-


chloro-5-(4,6-dichloro-[1,3,5]triazin-2-ylamino)-4-methyl-benzamide (101.0 mg, 87%) as white solid. MS (m/z) calcd for  $C_{11}H_8N_5O$  ( $MH^+$ ), 331; found, 331.

2. 3-(4,6-Dichloro-[1,3,5]triazin-2-ylamino)-4-methyl *N*-phenethyl-benzamide




Cyanuric chloride (0.74 g, 4.02 mL) was added to an acetone solution (15 mL) of 3-amino-4-methyl-*N*-phenethyl-benzamide (1.02 g, 4.02 mmol) at 0°C. The mixture was stirred for 1h at 0°C. Ice was added to the mixture and stirred for 15 min. The solvent was removed to afford 3-(4,6-dichloro-[1,3,5]triazin-2-ylamino)-4-methyl *N*-phenethyl-benzamide (1.52 g, 94%) as white solid MS (m/z) calcd for  $C_{19}H_{17}Cl_2N_5O$  ( $MH^+$ ), 402; found, 402.

*N,N*-Diethyl-4-methyl-benzamide




Dimethyl amine (13.00 g, 177.87 mmol, 18.40 mL) and pyridine (38.37 g, 485.10 mmol, 39.23 mL) were dissolved in 500 mL of anhydrous DCM under argon and cooled to 0°C. *p*-Tolyl chloride (25.00 g, 161.70 mmol), dissolved in 75 mL of anhydrous DCM, was added to the solution slowly. On completion of addition the solution was slowly warmed to room temp and stirred for 12h. The reaction mixture was poured into 1N HCl and the aqueous layer was extracted three times with ethyl acetate. The combined organic layers were washed with saturated sodium bicarbonate, water, brine and dried over anhydrous magnesium sulfate. The solution was filtered and the solvent removed under reduced pressure. The product was isolated by flash chromatography. (4:1 hexane/ethyl acetate) Yield 25.36 g.

*N,N*-Diethyl-2-formyl-4-methyl-benzamide




Tetramethylethylenediamine (6.20 g, 5336 mmol, 8.05 mL) was dissolved in anhydrous THF (100 mL) under argon and cooled to minus 78°C. *s*-Butyl lithium (1.30M, 53.36 mmol, 41.04 mL) was added to the solution slowly via syringe. The solution was stirred for 10 min at minus 78°C, then *N,N*-diethyl-4-methylbenzamide (9.28 g, 48.51 mmol), dissolved in 50 mL of anhydrous THF was added to the reaction mixture over 15 min. The reaction was stirred for 1h at minus 78°C, the DMF (7.09g, 97.02 mol, 7.51 mL) was added to the solution rapidly. The reaction mixture was allowed to slowly warm to room temp and stir for 12h. The reaction mixture was poured into 1N HCl and the aqueous layer was extracted three times with ethyl acetate. The combined organic layers were washed with saturated sodium bicarbonate, water, brine and dried over anhydrous magnesium sulfate. The solution was filtered and the solvent removed under reduced pressure. The product was isolated by flash chromatography. (3:1 hexane/ethyl acetate) Yield 7.98 g. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 1.08 (t, 3H), 1.32 (t, 3H), 2.46 (s, 3H), 3.13 (q, 2H), 3.42 (a, 2H), 7.28 (d, J = 8, 1H), 7.45 (d, J = 7, 1H), 7.77 (s, 1H), 10.01 (s, 1H).

3-Hydroxy-5-methyl 3H-isobenzofuran-1-one




*N,N*-diethyl-2-formyl-4-methylbenzamide (7.98 g, 36.39 mmol) was taken up in 100 mL of 6N HCl and heated to reflux for 48h. The reaction was then cooled to room temp and diluted with 50 mL of water. The aqueous layer was extracted three times with ethyl acetate. The combined organic layers were washed with saturated sodium bicarbonate, water, brine and dried over anhydrous magnesium sulfate. The solution was filtered and the solvent removed under reduced pressure. The product was isolated by flash chromatography. (3:1 hexane/ethyl acetate) Yield 4.66 g. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz): δ 2.47 (s, 3H), 6.05 (bs, 1H), 7.12 (s, 1H), 7.33 (d, J = 9, 1H), 7.95 (d, J = 9, 1H).


8-Methyl-3-phenyl-2,3-dihydro-9*bH*-oxazolo[2,3-*a*]isoindol-5-one

3-hydroxy-5-methyl-3*H*-isobenzofuran-1-one (4.66 g, 28.39 mmol) and *H*-phenylglycinol (3.89 g, 28.39 mmol) was taken up in dry toluene and heated to reflux under argon for 12h. The water generated was collected in a Dean-Stark trap. The reaction mixture was cooled to room temp and poured into 1N HCl and the aqueous layer was extracted three times with ethyl acetate. The combined organic layers were washed with saturated sodium bicarbonate, water, brine and dried over anhydrous magnesium sulfate. The solution was filtered and the solvent removed under reduced pressure. The product was isolated by flash chromatography. (4:1 hexane/ethyl acetate) Yield 5.20 g.


<sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) : δ 2.49 (s, 3H), 4.16 (dd, J = 7, 9Hz, 1H), 4.83 (dd, J = 8, 9Hz, 1H), 5.21 (t, J = 7, 1H), 6.01 (s, 1H), 7.31-7.45 (m, 1H), 7.73 (d, J = 8Hz, 1H).

2-(2-Hydroxy-1-phenyl-ethyl)-5-methyl-2,3-dihydro-isoindol-1-one

8-methyl-3-phenyl-2,3-dihydro-9*bH*-oxazolo[2,3-*a*]isoindol-5-one (5.20g, 19.60 mmol) was taken up in anhydrous DCM (100 mL) under argon and cooled to minus 78°C. Triethylsilane (9.12g, 78.40 mmol, 12.52 mL) was added via syringe followed by titanium tetrachloride in DCM (1.0M, 58.80 mmol, 58.80 mL). The solution was stirred at minus 78°C for 5h then allowed to warm to room temp and stir for 12h. The reaction was slowly poured into ice and the aqueous layer was extracted three times with ethyl acetate. The combined organic layers were washed with saturated sodium bicarbonate, water, brine and dried over anhydrous magnesium sulfate. The solution was filtered and the solvent removed under reduced pressure. The product was isolated by flash chromatography. (1:1 hexane/ethyl acetate) Yield 4.72 g. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) : δ 2.40 (s, 3H), 4.12-4.42 (m, 5H), 5.31 (dd, J = 4, 8Hz, 1H), 7.10-7.39 (m, 7H), 7.67 (d, J = 8, 1H).


Methanesulfonic acid 2-(5-methyl-1-oxo-1,3-dihydro-isoindol-2-yl)-2-phenyl-ethyl ester

2-(2-Hydroxy-1-phenyl-ethyl)-5-methyl-2,3-dihydro-isoindol-1-one (4.72 g, 17.66 mmol) and triethylamine (5.36 g, 53.97 mmol, 7.38 mL) were taken up in anhydrous DCM (50 mL), under argon and cooled to 0°C. Methanesulfonyl chloride (2.22 g, 19.43 mmol, 1.5 mL) was added to the reaction over 10 min. The reaction was stirred for 1h at 0°C then allowed to slowly warm to room temp and stirred for 4h. The reaction was slowly poured into saturated sodium bicarbonate and the aqueous layer was extracted three times with ethyl acetate. The combined organic layers were washed with 1N HCl, water, brine and dried over anhydrous magnesium sulfate. The solution was filtered and the solvent removed under reduced pressure. The product was used in the next step without further purification. Yield 5.61 g. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) : δ 2.44 (s, 3H), 3.01 (s, 3H), 4.15 (d, J = 16Hz, 1H), 4.43 (d, J = 17Hz, 1H), 4.77 (dd, J = 5, 11 Hz, 1H), 5.03 (dd, J = 9, 11Hz, 1H), 5.76 (dd, J = 5, 9Hz, 1H), 7.20-7.38 (, 7H), 7.76 (d, J = 8, 1H).



5-Methyl-2-(phenyl-allyl)-2,3-dihydro-isoindol-1-one

Under argon sodium metal (0.58 g, 24.37 mmol) was slowly added to anhydrous ethanol. After all the sodium was reacted methanesulfonic acid 2-(5-methyl-1-oxo-1,3-dihydro-isoindol-2-yl)-2-phenyl-ethyl ester (5.61 g, 16.25 mmol) dissolved in ethanol was added to the reaction mixture and the solution was stirred for 6h at room temp. The reaction was poured into water and the aqueous layer was extracted three times with ethyl acetate. The combined organic layers were washed with brine and dried over anhydrous magnesium sulfate. The solution was filtered and the solvent removed under reduced pressure. The product was used in the next step without further purification. Yield 3.64g. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) : δ 2.45 (s, 3H), 4.49 (s, 2H), 5.50 (s, 1H), 5.54 (s, 1H), 7.22-7.36 (m, 7H), 7.80 (d, J = 8Hz, 1H).




5-Methyl-2,3-dihydro-isoindol-1-one


5-Methyl-2-(phenyl-allyl)-2,3-dihydro-isoindol-1-one (3.64 g, 14.61 mmol) was taken up in a 50/50 mixture of ethanol-3M HCl (100 mL) and heated to 80°C for 12h. The reaction mixture was cooled and the ethanol was removed under reduced pressure. The aqueous layer was extracted three times with ethyl acetate and the combined organic layers were washed with water, brine and dried over anhydrous magnesium sulfate. The solution was filtered and the solvent removed under reduced pressure. The product was isolated by flash chromatography. (1:1 hexane/ethyl acetate) Yield 1.40g. <sup>1</sup>H NMR (CDCl<sub>3</sub>, 300 MHz) : δ 2.51 (s, 3H), 4.48 (s, 2H), 7.27-7.36 (m, 2H), 7.75 (d, J = 8Hz, 1H).

5-Methyl-4-nitro-2,3-dihydro-isoindol-1-one5-Methyl-6-nitro-2,3-dihydro-isoindol-1-one


5-Methyl-2,3-dihydro-isoindol-1-one (1.00g, 6.79 mmol) was taken up in sulfuric acid and cooled to 0°C. One equivalent of nitric acid was added to the solution and the mixture was allowed to slowly warm to room temp and stir for 12h. The reaction mixture was poured into ice water and the aqueous layer was extracted four times with ethyl acetate and the combined organic layers were washed with water, brine and dried over anhydrous magnesium sulfate. The solution was filtered and the solvent removed under reduced pressure. Two products were isolated by flash chromatography. (10% methanol-ethyl acetate) Yield 813.40 mg of the 4-nitro and 100 mg of the 6-nitro. <sup>1</sup>H NMR (300MHz, d<sub>6</sub>-DMSO) : 4-nitro δ 7.76 (s, 1H), 8.19 (s, 1H), 8.98 (bs, 1H); 6-nitro δ 7.69 (d, J = 9 Hz, 1H), 7.84 (d, J = 9Hz), 8.91 (bs, 1H).

6-Amino-5-methyl-2,3-dihydro-isoindol-1-one

5-Methyl-6-nitro-2,3-dihydro-isoindol-1-one (100.00 mg, 0.52 mmol) was taken up in ethyl acetate in a Paar vessel and flushed with argon. Palladium on carbon (25 mg) was added and the argon atmosphere was replaced with hydrogen at 50 psi. The vessel was shaken for 12h. The hydrogen was then replaced with argon and the catalyst was removed by filtration through celite. The solvent was removed under reduced pressure to yield 65.8 mg of the desired amine.  $C_9H_{10}N_2O$  MS  $m/e = 163.2$  (M+H).

4-Amino-5-methyl-2,3-dihydro-isoindol-1-one


5-Methyl-4-nitro-2,3-dihydro-isoindol-1-one (800.00 mg, 4.16 mmol) was taken up in ethyl acetate in a Paar vessel and flushed with argon. Palladium on carbon (100 mg) was added and the argon atmosphere was replaced with hydrogen at 50 psi. The vessel was shaken for 12h. The hydrogen was then replaced with argon and the catalyst was removed by filtration through celite. The solvent was removed under reduced pressure to yield 539.8 mg of the desired amine.  $C_9H_{10}N_2O$  MS  $m/e = 163.2$  (M+H).

2,2,2-Trifluoro-N-(2-methyl-5-nitro-phenyl)-acetamide

2-Methyl-5-nitro-phenylamine (3.00 g, 1972 mmol) was taken up in dry DCM, under argon, and triethylamine (3.99g, 39.44 mmol, 5.50 mL) and DMAP (0.24 g, 1.97 mmol) were added. The reaction was cooled to 0°C and trifluoroacetic anhydride (6.21g, 29.58 mmol, 4.18 mL) was added slowly via syringe. The reaction was allowed to slowly warm to room


temp and stirred for 12h. The reaction mixture poured into 1N HCl and the aqueous layer was extracted three times with ethyl acetate. The combined organic layers were washed with saturated sodium bicarbonate, water, brine and dried over anhydrous magnesium sulfate. The solution was filtered and the solvent removed under reduced pressure. The product was isolated by flash chromatography. (3:1 hexane/ethyl acetate) Yield 3.91 g.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz) :  $\delta$  2.43 (s, 3H), 7.45 (d,  $J = 9\text{Hz}$ , 1H), 8.10 (d,  $J = 9\text{Hz}$ , 1H), 8.69 (s, 1H).

*N*-(5-Amino-2-methyl-phenyl)-2,2,2-trifluoro-acetamide



2,2,2-Trifluoro-*N*-(2-methyl-5-nitro-phenyl)-acetamide (3.91 g, 15.78 mmol) was taken up in ethyl acetate in a Paar vessel and flushed with argon. Palladium on carbon (400 mg) was added and the argon atmosphere was replaced with hydrogen at 50 psi. The vessel was shaken for 12h. The hydrogen was then replaced with argon and the catalyst was removed by filtration through celite. The solvent was removed under reduced pressure to yield 3.27 g of the desired amine.  $\text{C}_9\text{H}_9\text{F}_3\text{N}_2\text{O}$  MS  $m/e = 219.1$  (M+H).


*N*-(5-Acetylamino-2-methyl-phenyl)-2,2,2-trifluoro-acetamide



*N*-(5-Amino-2-methyl-phenyl)-2,2,2-trifluoro-acetamide (3.27 gm 14.99 mmol) was taken up on anhydrous DCM (75 mL) and cooled to 0°C. Pyridine (3.56 g, 44.97 mmol, 3.64 mL) was added followed by a slow addition of acetyl chloride (1.18 g, 14.99 mol, 1.07 mL). The reaction was allowed to warm to room temp and stir for 30 min. The reaction mixture poured into 1N HCl and the aqueous layer was extracted three times with ethyl acetate. The combined organic layers were washed with saturated sodium bicarbonate, water, brine and dried over anhydrous magnesium sulfate. The solution was filtered and the solvent removed


under reduced pressure. The product was isolated by flash chromatography. (3:1 hexane/ethyl acetate) Yield 2.93 g.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz)  $\delta$  2.13 (s, 3H), 2.23 (s, 3H), 7.25 (d, J = 9Hz, 1H), 7.23 (d, J = 9Hz, 1H), 7.61 (s, 1H).

N-(3-Amino-4-methyl-phenyl)-acetamide



N-(5-Acetylamino-2-methyl-phenyl)-2,2,2-trifluoro-acetamide (2.93 g, 11.24 mmol) was taken up in methanol (50 mL) and sodium carbonate (5.96 g, 56.20 mmol) was added. The reaction was stirred at room temp for 12h. The reaction mixture was into water and the aqueous layer was extracted three times with ethyl acetate. The combined organic layers were washed with brine and dried over anhydrous magnesium sulfate. The solution was filtered and the solvent removed under reduced pressure. The product was utilized without further purification. Yield 1.60 g.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz) :  $\delta$  2.16 (s, 3H), 2.31 (s, 3H), 7.18 (d, J = 9Hz, 1H), 7.32 (d, J = 9Hz, 1H), 7.64 (s, 1H).


Methanesulfonic acid 4-methyl-3-nitro-benzyl ester



(4-Methyl-3-nitro-phenyl)-methanol (3.00 g, 17.95 mmol) was taken up in anhydrous DCM, under argon, and triethyl amine (5.45 g, 53.85 mmol, 7.51 mL) was added. The solution was cooled to 0°C and methanesulfonyl chloride (2.26 g, 19.74 mmol, 1.53 mL) was added slowly via syringe. The solution was allowed to warm to room temp and stir for 12h. The reaction mixture poured into 1N HCl and the aqueous layer was extracted three times with ethyl acetate. The combined organic layers were washed with water, brine and dried over anhydrous magnesium sulfate. The solution was filtered and the solvent removed under reduced pressure. The product was isolated by flash chromatography. (5:1 hexane/ethyl


acetate) Yield 2.00 g.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz) :  $\delta$  2.62 (s, 3H), 4.61 (s, 2H), 7.36 (d, J = 8Hz, 1H), 7.36 (d, J = 8Hz, 1H), 8.02 (s, 1H).

2-(Methyl-3-nitro-benzyl)-isoindole-1,3-dione




Methanesulfonic acid 4-methyl-3-nitro-benzyl ester (0.45 g, 1.83 mmol) was added to anhydrous DMF (20 mL), under argon, and potassium phthalimide (0.34 g, 1.83 mmol) was added. The reaction mixture was heated to 60°C for 12h. The reaction mixture was cooled and poured into 1N HCl and the aqueous layer was extracted three times with ethyl acetate. The combined organic layers were washed with water, brine and dried over anhydrous magnesium sulfate. The solution was filtered and the solvent removed under reduced pressure. The product was isolated by flash chromatography. (4:1 hexane/ethyl acetate) Yield 0.45 g.  $^1\text{H}$  NMR ( $\text{CDCl}_3$ , 300 MHz) :  $\delta$  2.58 (s, 3H), 4.88 (s, 2H), 7.30 (d, J = 7Hz, 1H), 7.57 (d, J = 7Hz, 1H), 7.24-7.77 (m, 2H), 7.84-7.89 (m, 2H), 8.02 (s, 1H).

2-(3-Amino-4-methyl-benzyl)-isoindole-1,3-dione



2-(Methyl-3-nitro-benzyl)-isoindole-1,3-dione (0.45 g, 1.52 mmol) was taken up in ethyl acetate in a Paar vessel and flushed with argon. Palladium on carbon (100 mg) was added and the argon atmosphere was replaced with hydrogen at 50 psi. The vessel was shaken for 12h. The hydrogen was then replaced with argon and the catalyst was removed by filtration through celite. The solvent was removed under reduced pressure to yield 0.40 g of the desired amine.  $\text{C}_{16}\text{H}_{14}\text{N}_2\text{O}_2$  MS  $m/e$  = 267.3 (M+H).

General Procedure for Synthesis of N-alkyl-3-(4,6-dichloro-[1,3,5]triazin-2-ylamino)-4-methyl-benzamides




4-Methyl-3-nitro-benzoyl chloride (1 molar equivalent) was dissolved in  $\text{CH}_2\text{Cl}_2$ , and the solution was cooled to  $0^\circ\text{C}$ . The appropriate amine (2 M equiv) was added drop wise to the acid chloride, and the reaction stirred at  $0^\circ\text{C}$  for 5 min. The ice bath was removed and reaction continued to stir for 3 h. The solution was washed with brine, dried ( $\text{Na}_2\text{SO}_4$ ), and concentrated *in vacuo*. The resulting amide was purified by silica gel chromatography.

The amide was then dissolved in EtOAc, and a catalytic amount of Pd/C was added. The solution was pressurized to 50 psi  $\text{H}_2$  for 15 h. The solution was filtered through celite and concentrated *in vacuo*. The aniline was used without further purification.

A solution of aniline (1 molar equivalent) in acetone was added drop wise to a  $0^\circ\text{C}$  solution of cyanuric chloride (1 molar equivalent) in acetone. The cold bath was removed, and the reaction stirred at room temp for 3h. Acetone was removed *in vacuo*. The resulting solid was washed with hexane then dried under high vacuum.

### Carbamates



To the solution of 4-methyl-3-nitroaniline (0.75 g, 5.0 mmol) in DCM (10 mL) cooled in an ice-bath was added methyl chloroformate (1.01 equiv.) and Hunig's base (1.1 equiv.). The solution was stirred at  $0^\circ\text{C}$  for 0.5 h. The reaction mixture was diluted with ethyl acetate (20 mL) and washed with aqueous ammonium chloride solution twice, and brine twice. The organic layer was dried with anhydrous sodium sulfate and concentrated under vacuum. The crude product was then dissolved in ethyl acetate (20 mL) and the solution was added with 10% palladium on carbon powder. The reaction mixture was put onto the hydrogenation apparatus. Hydrogenolysis was proceeded at room temp for 0.5 h. The reaction mixture was filtered and the filtrate was concentrated under vacuum. Purification of the crude product with flash chromatography gave 0.75 g of 3-amino-4-methylphenylamino methyl carbamate (yield 85%).

In a 50 mL round-bottomed flask was added 3-amino-4-methylphenylamino methyl carbamate (0.75 g) and acetone (10 mL). The solution was cooled with an ice-bath and added with trichlorotriazine (1.0 equiv.). The mixture was stirred at  $0^\circ\text{C}$  for 5 min before the addition of sat. aq. sodium bicarbonate solution (20 mL). Continued stirring at  $0^\circ\text{C}$  for 15 min, the mixture was filtered and washed with cold ethanol. The solid was dried and dissolved into anhydrous DMF (10 mL). Cooled in an ice-bath, the solution was added with  $N$ -methylneopentylamine hydrochloride (1.0 equiv.) and Hunig's base (1.2 equiv.). The solution was stirred at  $0^\circ\text{C}$  for 0.5h before the addition of ethyl acetate and aq. solution of ammonium chloride. The organic layer was separated and washed with aq. ammonium


solution and brine twice, dried with anhydrous sodium sulfate and concentrated under vacuum. The crude product was purified with flash chromatography.

The above-obtained product (80 mg) was dissolved into DMSO (1 mL). The solution was added 1-Boc-(3*R*)-aminopyrrolidine (1.5 equiv.) and Hunig's base (2 equiv.). The mixture was heated to 80°C for overnight. The reaction mixture was cooled to room temp and diluted with ethyl acetate and aq. ammonium chloride solution. The organic layer was separated and washed with aq. ammonium solution and brine twice, dried with anhydrous sodium sulfate and concentrated under vacuum. The crude was then dissolved into an 50% solution of trifluoroacetic acid in DCM and stirred at room temp for 2h. The solvent was removed under vacuum. The product was purified with HPLC and 50.1 mg of final compound was obtained.

#### Solid Phase Preparations of Compounds of Formula I

Compounds of Formula I may also be prepared on solid phase. Typically, an amino-functionalized resin, such as PEG-grafted polystyrene beads (*e.g.*, ArgoGel™), may be modified by reaction with *bis*-Fmoc lysine to increase the available reaction sites for ligand attachment. After deprotection, an aldehyde linker may be attached via the free amine sites. Reductive amination with a primary amine yields a resin-bound secondary amine. The following descriptions are illustrative of methods of preparing compounds of Formula I on solid phase.


##### Method 1




ArgoGel resin (3.0 g) with acid cleavable linker in a shaking vessel was washed with 1,2-dichloroethane twice. After draining, 120 mL of 1,2-dichloroethane was added, followed with the addition of cyclopentylamine (20 equivalents). The pH of the reaction mixture was adjusted to 5 with the addition of acetic acid. The reaction mixture was shaken at room temp for 15 min, and added with sodium triacetoxyborohydride (20 equivalents). After completion



of the addition, the reaction mixture was shaken at room temp for 16h. The resin was then filtered and washed with methanol and DCM (5 cycles).




The ArgoGel resin obtained above was washed with DMF twice. After draining, 50 mL of anhydrous DMF and Hunig's base (10 equivalents) were added, followed with the addition of 2-(5-aminocarbonyl-2-methyl)phenylamino-4,6-dichlorotriazine (3.0 equivalents). The reaction was allowed to proceed at room temp for 4h. The resin was then filtered and washed with methanol and DCM (5 cycles), and dried over vacuum.




ArgoGel resin (50 mg) obtained above was put into a small reaction vial. To the vial was added with anhydrous *n*-BUOH (1.0 mL) and 1-*N*-Boc-(3*R*)-aminopyrrolidine (0.5 mmol). The reaction mixture was heated to 70°C for 16h. The resin was then filtered and washed with methanol and DCM (5 cycles) and treated with a 50% solution of trifluoroacetic acid in DCM. The product was collected through filtration and purified by HPLC.

#### Method 2

This method allows for *N*-derivatization the solid supports.





The TentaGel™ resin (3.5 g) attached with the acid cleavable linker was washed with 1,2-dichloroethane twice (5 min shaking each time). After drained, the resin was added with 1,2-dichloroethane (30 mL). (3*R*)-amino-1-pyrrolidine allyl carbamate (1.00 g) was added and the pH of the solution was adjusted to 5 by the addition of acetic acid. The reaction mixture was shaken at room temp for 15 min, before the addition of sodium triacetoxyborohydride (10 equiv.). The reaction mixture was shaken at room temp for overnight. The resin was filtered and washed with methanol, DCM, and THF. Then it was dried over vacuum.


0.9 g of the above-obtained resin was washed with DMF twice and suspended into DMF (8 mL). To the resin suspension, Hunig's base (5.0 equiv.) was added, and then the dichlorotriazine derivative (3.0 equiv.). The reaction mixture was shaken at room temp for 4h. The resin was filtered and washed with DMF, methanol, DCM, and then suspended in DMSO (6 mL). The suspension was added with 1-isobutyl-1-methylamine (10 equiv.). The reaction mixture was heated to 80°C overnight. The resin was filtered and washed with methanol, DCM, and THF. Then it was dried over vacuum.

50 mg of the above-obtained resin was suspended into THF (3 mL). Tetrakis(triphenylphosphine)palladium(0) (0.15 g) and 5,5-dimethyl-1,3-cyclohexane-dione (10 equiv.) were added. The reaction mixture was shaken at room temp for overnight. The resin was washed with 0.5 % solution of sodium diethyldithiocarbamate in DMF, and then 0.5% DMF solution of Hunig's base before it was washed with methanol, DCM.

The resin was washed with 1,2-dichloroethane twice and suspended in 1,2-dichloroethane (3 mL). Acetone (0.1 mL) and sodium triacetoxyborohydride (10 equiv.) were

added. The reaction mixture was shaken at room temp for overnight. The resin was filtered and washed with methanol, DCM, and cleaved with TFA/DCM (1:1). The cleavage gave the crude final product in an 80% overall yield.


### Method 3 - Attachment of Acid Cleavable Linker to Resin



*Bis*-Fmoc lysine was coupled to amino-functionalized TentaGel™ by amide bond formation. Coupling was achieved by reacting a suspension of the resin (40g, 11.2 mmol) in 100 mL of DMF with *bis*-Fmoc lysine (20 g, 33.8 mmol), HOBt (5.2 g, 33.9 mmol) and DIC (10.6 mL, 67.6 mmol). The suspension was shaken overnight, then drained and washed in succession with MeOH, DMF and DCM, then dried *in vacuo*.


A suspension of resin in 1:3 piperidine:DMF (50 mL) was shaken about 2h, then washed with MeOH, DMF and DCM. This diamine resin (40g, 20 mmol) was suspended in 160 mL of DMF, and treated with MPB (9.6 g, 40.3 mmol) and HOBt (6.2 g, 40.5 mmol). DIC (12 mL, 76.6 mmol) was added after 30 min. The suspension was shaken overnight, then drained and the resin was washed with MeOH, DMF and DCM. The MPB resin was dried *in vacuo*.

### Attachment of (3*R*)-3-Amino-pyrrolidine-1-carboxylic acid *t*-butyl ester to resin




Pyrrolidine amine (0.5 mg, 2.68 mmol) was added to a suspension of resin (5g, 2.5 mmol) in 45 mL of DCE and the mixture was shaken 30 min. Sodium triacetoxyborohydride (0.8 g, 3.7 mmol) was then added and the resulting mixture was shaken for 18h and the suspension was drained. The resin was washed with MeOH, DMF and DCM, and dried overnight under vacuum.

Coupling of resin-linked amino-pyrrolidine with 3-(4,6-dichloro-[1,3,5]triazin-2-ylamino)-4-methyl-benzamide



A suspension of the resin (2.7 g, 1.35 mmol), DIEA (0.5 mL) and 3-(4,6-dichloro[1,3,5]triazin-2-ylamino)-4-methyl-benzamide (0.5 g, 1.67 mol) in 10 mL of dry THF was stirred for 16h at 70°C. The suspension was drained, the resin was washed with MeOH, DMF and DCM and dried under vacuum.


3-[4-(*i*-Butyl-methyl-amino)-6-(3*R*)-(pyrrolidin-3-ylamino)-[1,3,5]triazin-2-ylamino]-4-methyl-benzamide



A suspension of the resin (0.1 g, 0.05 mmol) and *N*-methylisobutylamine (0.1 mL, 0.8 mmol) in 1 mL of dry THF was stirred for 3h at 80°C. The suspension was drained, the resin was washed with MeOH, DMF, and DCM. In order to cleave the product from the resin, the resin was treated with 1 mL of TFA for 1h with stirring. After filtration and concentration of


the solution, the product was purified by Prep-HPLC as TFA salt (4.2 mg, 21%,  $C_{20}H_{30}N_8O$ , ms m/z 399 (M+H)<sup>+</sup>).

3-[4-(6,6-Dimethyl-bicyclo[3.1.1]hept-2-ylmethoxy)-6-(pyrrolidin-3-ylamino)-[1,3,5]triazin-2-ylamino]-4-methyl-benzamide




To a suspension of the resin (0.1 g, 0.05 mmol), DIEA (0.1 mL) and (1S,2S,5S)-(-)-myrtanol (0.08 mL, 0.5 mmol) in 1 mL of dry THF was added NaH (60% in oil, 0.04 g, 1 mmol), and the resulting suspension was stirred for 16h at 75°C. The suspension was drained, the resin was washed with MeOH, DMF, and DCM. In order to cleave the product from the resin, the resin was treated with 1 mL of TFA for 1h with stirring. After filtration and concentration of the solution, the product was purified by Prep-HPLC as a TFA salt (1.2 mg, 5.2%,  $C_{25}H_{35}N_7O_2$ , MS m/z 466 (M+H)<sup>+</sup>).

3-[4-(3-Chloro-phenyl)-6-(pyrrolidin-3-ylamino)-[1,3,5]triazin-2-ylamino]-4-methyl benzamide



A suspension of the resin (0.1 g, 0.05 mmol), tetrakis(triphenylphosphine)-palladium(0) (0.015 g, 0.012 mmol), and 3-chloro-phenylzinc iodide (0.5M in THF, 1.5 mL, 0.75 mmol) was stirred for 16h at 80°C. The suspension was drained, the resin was washed with water, THF, MeOH, DMF, and DCM. In order to cleave the product from the resin, the resin was treated with 1 mL of TFA for 2h under stirring. After filtration and concentration of the solution, the product was purified by Prep-HPLC as a TFA salt (1.9 mg, 9%,  $C_{21}H_{22}ClN_7O$ , MS m/z 424 (M+H)<sup>+</sup>).


3-[4-Isobutylsulfonyl-6-(pyrrolidin-3-ylamino)-[1,3,5]triazin-2-ylamino]-  
-4-methyl-benzamide



To a stirring suspension of NaH (60% in oil, 0.06 g, 1.5 mmol) in 2 mL of dry THF was added *i*-butylthiol (0.07 mL, 0.6 mmol) dropwise at room temp. After the evolution of the hydrogen gas ceased, this mixture was added to the resin (0.1 g, 0.05 mmol), and the resulting suspension was stirred for 30 min at room temp and 16h at 80°C. The suspension was drained, the resin was washed with MeOH, DMF, and DCM. In order to cleave the product from the resin, the resin was treated with 1 mL of TFA for 1h under stirring. After filtration and concentration of the solution, the product was purified by Prep-HPLC as a TFA salt (3.5 mg, 5.2%, C<sub>19</sub>H<sub>27</sub>N<sub>7</sub>OS. MS m/z 402 (M+H)<sup>+</sup>.


General Procedures for Synthesis of 3-(4,6-Bis-alkylamino-pyrimidin-2-ylamino)-

-4-methyl-benzamides.



3-[4-Cyclopentylamino-6-[(2,2-dimethyl-propyl)-methyl-amino]-pyrimidin-2-ylamino]-

-4-methyl-benzamide




3-Amino-4-methyl-benzamide (1 molar equivalent) was added to a room temp solution of trifluoropyrimidine (1 molar equivalent) and DIEPA (1.5 molar equivalents), in THF. The reaction stirred for 24h, then was concentrated *in vacuo*. The resulting mixture of 2- and 4-pyrimidine products were separated by silica gel chromatography.

The substituted pyrimidine (34 mg, 0.12 mmol), resin bound-amine (140 mg, 0.07 mmol) and DIPEA (50  $\mu$ L, 0.28 mmol) in DMSO (1 mL) was heated to 120°C for 24h. The resin was washed with DMF (3x) and DCM (3x).

The resulting resin was reacted with amine (120 mg 1.1 mmol) in DMSO (0.5 mL) at 80°C for 18h. The resin was washed with DMF (3x), MeOH (3x), DCM (3x), then treated with TFA to release the product. The crude product was purified by preparative HPLC. MS ( $m/z$ ) calcd for  $C_{23}H_{35}N_6O$  ( $MH^+$ ), 411; found, 411.

N-(3-{4-Cyclopentylamino-6-[(2,2-dimethyl-propyl)-methyl-amino]-pyrimidin-2-ylamino}-4-methyl-benzyl)-acetamide











The resin-bound phthalimide was prepared using standard methods. A suspension of resin (200 mg) in 2M hydrazine/ethanol (20 mL) was stirred for 4h at room temp. The resin was washed with MeOH (3x), DMF (3x), DCM (3x), then dried under high vacuum.

Acetic anhydride (40  $\mu$ L, 0.42 mmol), was added to a vial containing resin (80 mg, 0.04 mmol), DMAP (cat.) in 10% pyridine/DCM. The reaction stirred for 16h at room temp. The resin was washed with DCM (3x), MeOH (3x), DCM (3x). Upon stirring of the resin in 1 mL of TFA for 3h, the product was released. The solution was concentrated *in vacuo* and the residue was purified by Prep-HPLC. MS ( $m/z$ ) calcd for  $C_{25}H_{39}N_6O$  ( $MH^+$ ), 440; found, 440.















It should be understood that while this invention has been described herein in terms of specific embodiments set forth in detail, such embodiments are presented by way of

illustration of the general principles of the invention, and the invention is not necessarily limited thereto. Certain modifications and variations in any given material, process step or chemical formula will be readily apparent to those skilled in the art without departing from the true spirit and scope of the present invention, and all such modifications and variations should be considered within the scope of the claims that follow.

Table 1					
#	MW	#	MW		
1	347.81		2	398.515	
3	444.543		4	446.559	
5	464.618		6	439.524	
7	476.629		8	458.57	



9	493.015		10	444.543	
11	395.511		12	481.004	
13	448.531		14	476.541	
15	436.564		16	444.543	
17	458.57		18	466.977	
19	446.559		20	464.618	
21	476.629		22	434.504	
23	378.436		24	342.407	

25	435.536		26	328.376	
27	396.499		28	419.489	
29	461.57		30	492.628	
31	492.628		32	465.602	
33	478.645		34	398.515	
35	464.618		36	399.499	
37	485.036		38	398.515	

39	412.542		40	412.542	
41	478.645		42	487.612	
43	476.629		44	464.618	
45	486.624		46	424.553	
47	384.484		48	403.49	
49	410.526		50	438.584	
51	466.634		52	438.58	
53	450.522		54	426.569	





















55	488.64		56	398.515	
57	384.488		58	412.542	
59	468.565		60	424.553	

Table 1

#	MW	#	MW
61	398.515	62	487.612
63	398.515	64	398.515
65	464.618	66	398.515

67	465.646		68	384.488	
69	384.488		70	410.526	
71	622.859		72	510.687	
73	426.569		74	484.605	
75	412.542		76	438.58	
77	460.586		78	397.527	
79	427.553		80	518.666	
81	489.628		82	532.649	















83	489.628		84	488.64	
85	412.542		86	513.65	
87	523.085		88	412.542	
89	488.64		90	426.569	
91	440.596		92	495.031	
93	426.569		94	383.46	
95	518.666		96	484.605	













97	489.628		98	502.667	
99	410.526		100	424.553	
101	502.667		102	502.667	
103	456.595		104	502.667	
105	502.667		106	383.5	
107	502.667		108	426.569	
109	517.682		110	432.96	

111	446.987		112	415.929	
113	429.956		114	412.542	

Table 1					
#	MW	#	MW	#	MW
115	532.649		116	506.63	
117	502.667		118	532.693	
119	489.628		120	502.623	
121	489.628		122	489.628	
123	506.638		124	412.542	



125	513.65		126	506.63	
127	523.085		128	557.53	
129	513.65		130	516.694	
131	412.542		132	426.569	
133	397.527		134	502.667	
135	440.596		136	412.542	
137	329.364		138	424.553	

















139	438.58		140	432.96	
141	446.987		142	516.694	
143	516.694		144	516.694	
145	530.721		146	544.748	
147	503.655		148	503.655	
149	503.655		150	412.542	

151	530.721		152	518.666	
153	504.639		154	504.639	
155	523.085		156	556.637	
157	503.655		158	470.622	

Table 1					
#	MW		#	MW	
159	482.677		160	480.661	
161	412.542		162	426.569	

163	454.623		164	494.688	
165	496.704		166	504.639	
167	504.639		168	411.554	
169	396.499		170	502.667	
171	440.596		172	454.623	
173	470.622		174	468.65	
175	490.656		176	518.666	

177	452.607		178	466.634	
179	484.649		180	426.569	
181	440.596		182	410.526	
183	424.553		184	410.526	
185	424.553		186	412.542	
187	466.634		188	480.661	
189	470.622		190	454.623	
191	482.677		192	482.677	
193	454.623		194	482.677	

195	428.497		196	468.65	
197	484.649		198	440.596	
199	452.485		200	480.539	
201	454.623		202	440.596	
203	426.569		204	468.65	
205	412.542		206	383.5	
207	397.527		208	423.908	
209	426.569		210	426.569	
















211	426.569		212	488.64	
213	476.604		214	503.655	

Table 1					
#	MW	#	MW	#	MW
215	426.569		216	502.667	
217	456.595		218	470.622	
219	440.596		210	502.667	
221	516.694		222	427.553	
223	531.709		224	517.682	

225	502.667		226	502.667	
227	440.596		228	454.623	
229	426.569		230	426.569	
231	468.65		232	475.601	
233	489.628		234	508.593	
235	401.537		236	415.564	
237	454.623		238	480.661	
239	468.65		240	494.688	



241	488.64		242	438.58	
243	413.526		244	448.594	
245	412.542		246	413.526	
247	482.677		248	424.553	
249	424.553		250	454.623	
251	426.569		252	481.523	
253	399.543		254	502.667	
255	516.694		256	495.55	

257	456.595		258		BLANK
259	412.542		260	398.515	
261	413.526		262	427.553	
263	438.58		264	426.569	
265	452.607		266	397.527	
267	480.539		268	494.566	
269	398.559		270	442.568	
271	440.64		272	440.64	

273	562.763		274	426.569	
275	440.596		276	452.485	
277	460.586		278	460.586	
279	557.53		280	454.623	
281	438.58		282	440.596	
283	440.596		284	454.623	
285	438.58		286	452.607	
287	492.672		288	506.699	















289	426.569		290	454.623	
291	527.677		292	456.595	

Table 1					
#	MW	#	MW	#	MW
293	482.511		294	513.65	
295	442.568		296	428.541	
297	472.562		298	496.538	
299	456.595		300	465.606	
301	451.579		302	426.569	

303	426.569		304	454.623	
305	458.567		306	464.574	
307	470.578		308	550.668	
309	442.568		310	442.568	
311	456.595		312	470.622	
313	506.63		314	506.63	
315	492.628		316	442.568	
317	484.649		318	437.552	

319	428.541		320	518.666	
321	518.666		322	518.666	
323	463.586		324	532.476	
325	527.674		326	481.576	
327	478.601		328	456.551	
329	478.601		330	500.648	
331	484.649		332	481.605	
333	456.595		334	456.551	
335	392.891		336	387.488	

337	458.611		338	456.595	
339	470.622		340	470.622	
341	486.621		342	373.461	
343	401.515		344	527.674	
345	441.58		346	429.569	
347	442.568		348	424.509	
349	456.595		350	469.634	
351	375.448		352	375.448	
353	441.58		354	467.578	











355	484.649		356	401.515	
357	484.649		358	387.488	
359	400.527		360	483.661	
361	470.622		362	483.661	
363	483.661				




Table 2




#	R <sup>20</sup>	R <sup>21</sup>	Compound	HPLC Ret. Time(min)	Mass Spec MH <sup>+</sup> (m/z)
364	CH <sub>3</sub>		O	2.89	466
365	H		P	3.01	458
366	H		Q	2.86	452
367	OCH <sub>3</sub>		R	2.99	488
368	OCH <sub>3</sub>		S	2.87	482
369	OCH <sub>3</sub>		T	2.80	460
370	CH <sub>3</sub>		U	2.80	444
371	H		V	2.70	430

Table 3



#	R <sup>22</sup>	R <sup>23</sup>	Compound	HPLC Ret. Time(min)	Mass Spec MH <sup>+</sup> (m/z)
372	H		C <sub>1</sub>	2.27	445
373	OCH <sub>3</sub>		D <sub>1</sub>	2.5	475
374	H		E <sub>1</sub>	1.99	417
375	OCH <sub>3</sub>		F <sub>1</sub>	2.1	447


Table 4



#	R <sup>24</sup>	R <sup>25</sup>	Compound	HPLC Ret. Time(min)	Mass Spec MH <sup>+</sup> (m/z)
376	CH <sub>3</sub>		K <sub>1</sub>	2.71	456
377	OCH <sub>3</sub>		L <sub>1</sub>	2.68	472
378	H		M <sub>1</sub>	2.57	436
379	CH <sub>3</sub>		N <sub>1</sub>	2.63	450
380	OCH <sub>3</sub>		O <sub>1</sub>	2.61	466
381	H		P <sub>1</sub>	2.51	414
382	CH <sub>3</sub>		Q <sub>1</sub>	2.59	428
383	OCH <sub>3</sub>		R <sub>1</sub>	2.57	444

What is claimed is:

1. A compound of Formula I, or a salt thereof,



wherein:

V is chosen from  $-\text{CHR}^5$ -,  $-\text{NR}^5$ -,  $-\text{O}$ -, and  $-\text{S}$ -;

W, X, and Y are independently chosen from  $-\text{CH}=\text{}$  and  $-\text{N}=\text{}$ ;

Z is chosen from halogen, alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, heteroaryl, substituted heteroaryl,  $-\text{SR}^3$ ,  $-\text{O}-\text{R}^3$ , and  $-\text{N}(\text{R}^1)(\text{R}^2)$ ;

$-\text{N}(\text{R}^1)(\text{R}^2)$  taken together may form a heteroaryl, substituted heteroaryl, heterocyclyl or substituted heterocyclyl or


$\text{R}^1$  is chosen from hydrogen, alkyl and substituted alkyl; and

$\text{R}^2$  is chosen from hydrogen, alkyl, substituted alkyl, alkoxy, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, heteroaryl, and substituted heteroaryl;

$\text{R}^3$  is chosen from hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, heteroaryl and substituted heteroaryl;

$\text{R}^5$  is chosen from hydrogen and alkyl;

$\text{R}^6$  is



$\text{R}^7$  is chosen from hydrogen,  $-\text{N}(\text{R}^{31})(\text{R}^{32})$ , halogen, cyano, alkyl, substituted alkyl, alkoxy, and alkylthio;

$\text{R}^8$  is chosen from hydrogen and halogen;

$\text{R}^9$  is chosen from nitro, carboxy,  $-\text{C}(\text{O})\text{N}(\text{R}^{31})(\text{R}^{32})$ ,  $-\text{SO}_2\text{N}(\text{R}^{31})(\text{R}^{32})$ ,

$-N(R^{33})SO_2R^{34}$ ,  $-C(O)N(R^{33})N(R^{31})(R^{32})$ ,  $-N(R^{33})C(O)R^{34}$ ,  $-CH_2N(R^{33})C(O)R^{34}$ ,  
 $-N(R^{31})(R^{32})$ ,  $-CH_2OC(O)R^{34}$ , alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl,  
 substituted aryl, heterocyclyl, substituted heterocyclyl, heteroaryl, substituted heteroaryl, and  
 $-C(O)R^{10}$ ;

$R^{10}$  is chosen from heterocyclyl, substituted heterocyclyl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, alkyl, substituted alkyl, and  $-N(R^{31})(R^{32})$ ; or

$R^8$  and  $R^9$  taken together may form  $-C(O)N(R^{33})CH_2-$  or  $-C(O)N(R^{33})C(O)-$ ;

$R^{31}$  and  $R^{33}$  are independently chosen from hydrogen, alkyl, and substituted alkyl;

$R^{32}$  is chosen from hydrogen, alkyl, substituted alkyl, alkoxy, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, aryloxy, heterocyclyl, substituted heterocyclyl, heteroaryl and substituted heteroaryl;

$R^{34}$  is chosen from alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, heteroaryl, and substituted heteroaryl;

when V is  $-NR^5$ ,  $-N(R^5)(R^6)$  taken together may form heterocyclyl, substituted heterocyclyl, heteroaryl, or substituted heteroaryl;


$R^{11}$  is chosen from halogen,  $OR^{13}$ , and  $-N(R^{12})(R^{13})$ ;

$R^{12}$  is chosen from hydrogen, alkyl, and substituted alkyl;

$R^{13}$  is  $-(CH_2)_mR^{14}$ ;


m is 0, 1, 2 or 3;

$R^{14}$  is chosen from hydrogen, alkyl, substituted alkyl,  $-C(O)N(R^{31})(R^{32})$ ,  $-N(R^{33})C(O)R^{34}$ , aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, heteroaryl, substituted heteroaryl, and



$R^{15}$  is chosen from hydrogen, alkyl, substituted alkyl, alkenyl,  $-C(O)$ -alkyl,  $-C(O)$ -substituted alkyl,  $-C(O)$ -aryl,  $-C(O)$ -substituted aryl,  $-C(O)$ -alkoxy, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, heteroaryl, and substituted heteroaryl;

$R^{16}$  is chosen hydrogen, alkyl, substituted alkyl, and



$R^{17}$  is chosen from hydrogen, alkyl, substituted alkyl,  $-C(O)$ -alkyl,  $-C(O)$ -substituted alkyl,  $-C(O)$ -aryl, and  $-C(O)$ -substituted aryl; or  $-N(R^{12})(R^{13})$  taken together may form a heterocyclyl, substituted heterocyclyl, heteroaryl, or substituted heteroaryl.

2. A compound of Claim 1 including a pharmaceutically acceptable salt thereof wherein:

two or more of W, Y and X are  $=N-$ ;

V is  $-CHR^5$ ,  $-NR^5$ , or  $-O-$ ;

Z is  $-N(R^1)(R^2)$ ,  $-S$ -aryl, or  $S$ -substituted aryl;

$R^1$  is hydrogen or alkyl;

$R^2$  is alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, heteroaryl, or substituted heteroaryl;

$R^5$  is hydrogen;

$R^7$  is hydrogen, alkyl, substituted alkyl, alkoxy, or halogen;

$R^8$  is hydrogen;

$R^9$  is  $-C(O)R^{10}$ ;

$R^{10}$  is alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heterocyclyl, substituted heterocyclyl, heteroaryl, substituted heteroaryl, or  $-N(R^{31})(R^{32})$ ;

$R^{31}$  is hydrogen, alkyl, or substituted alkyl;

$R^{32}$  is hydrogen, alkyl, substituted alkyl, alkoxy, aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, heteroaryl, or substituted heteroaryl;


$R^{11}$  is  $-N(R^{12})(R^{13})$ ;

$R^{12}$  is hydrogen, alkyl, or substituted alkyl;

$R^{13}$  is  $-(CH_2)_m R^{14}$ ;

m is 0, 1, 2 or 3;

$R^{14}$  is hydrogen, alkyl substituted alkyl,  $-C(O)N(R^{31})(R^{32})$ ,  $-N(R^{33})C(O)R^{34}$ , aryl, substituted aryl, cycloalkyl, substituted cycloalkyl, heterocyclyl, substituted heterocyclyl, heteroaryl, substituted heteroaryl or



$R^{15}$  is hydrogen, alkyl or substituted alkyl;

$R^{16}$  is hydrogen or alkyl; or

$-N(R^{12})(R^{13})$  taken together may form a heterocyclyl or substituted heterocyclyl;

$R^{33}$  is hydrogen, alkyl, or substituted alkyl; and

$R^{34}$  is alkyl, substituted alkyl, aryl or substituted aryl.

3. A compound of Claim 2 including a pharmaceutically acceptable salt thereof wherein:

two or more of W, Y and X are =N-;

V is  $-NH-$ , or  $-O-$ ;

Z is  $-N(R^1)(R^2)$ ,  $-S$ -aryl, or  $S$ -substituted aryl;

$R^1$  is hydrogen or alkyl or 1 to 4 carbons;

$R^2$  is alkyl or substituted alkyl wherein alkyl is of 1 to 8 carbons;

$R^7$  is hydrogen, alkyl, of 1 to 4 carbons, alkoxy of 1 to 4 carbons, or halogen;

$R^8$  is hydrogen;


$R^9$  is  $-C(O)R^{10}$ ;

$R^{10}$  is  $-NH_2$ ,  $-NH$ -alkyl,  $-NH$ -alkoxy,  $-NH$ -phenyl, or  $-NH-CH_2$ -phenyl wherein alkyl and alkoxy are of 1 to 6 carbons;

$R^{11}$  is  $-N(R^{12})(R^{13})$  wherein  $N(R^{12})(R^{13})$  taken together form a monocyclic heterocyclyl or substituted heterocyclyl of 5 to 7 atoms containing 1, 2, or 3 additional nitrogen atoms or wherein

$R^{12}$  is hydrogen;

$R^{13}$  is alkyl of 1 to 4 carbons or



$R^{15}$  and  $R^{16}$  are independently selected from hydrogen and methyl.

4. A compound of Claim 3 including a pharmaceutically acceptable salt thereof wherein:

W, Y and X are each =N-;

V is -NH-, or -O-;

Z is -N(R<sup>1</sup>)(R<sup>2</sup>), -S-aryl, or S-substituted aryl;

R<sup>1</sup> is hydrogen or methyl;

R<sup>2</sup> is alkyl of 1 to 8 carbons;

R<sup>7</sup> is hydrogen, methyl, methoxy, Cl, Br, or F;

R<sup>8</sup> is hydrogen;

R<sup>9</sup> is -C(O)R<sup>10</sup>;

R<sup>10</sup> is -NH<sub>2</sub>, -NH-alkyl, -NH-alkoxy, -NH-phenyl, or -NH-CH<sub>2</sub>-phenyl wherein alkyl and alkoxy are of 1 to 6 carbons; and

R<sup>11</sup> is -N(R<sup>12</sup>)(R<sup>13</sup>) wherein N(R<sup>12</sup>)(R<sup>13</sup>) taken together form a monocyclic heterocyclyl or substituted heterocyclyl of 5 to 7 atoms containing 1, 2, or 3 additional nitrogen atoms.

5. A compound of Claim 3 including a pharmaceutically acceptable salt thereof wherein:

W, Y and X are each =N-;

V is -NH-, or -O-;

Z is -N(R<sup>1</sup>)(R<sup>2</sup>), -S-aryl, or S-substituted aryl;

R<sup>1</sup> is hydrogen or methyl;


R<sup>2</sup> is alkyl of 1 to 8 carbons;

R<sup>7</sup> is hydrogen, methyl, methoxy, Cl, Br, or F;

R<sup>8</sup> is hydrogen;

R<sup>9</sup> is -C(O)R<sup>10</sup>;

R<sup>10</sup> is -NH<sub>2</sub>, -NH-alkyl, -NH-alkoxy, -NH-phenyl, or -NH-CH<sub>2</sub>-phenyl wherein alkyl and alkoxy are of 1 to 6 carbons;





wherein alkyl is of 1 to 4 carbons; and

$R^{15}$  and  $R^{16}$  are independently selected from hydrogen and methyl.

6. A compound of Claim 4 including a pharmaceutical acceptable salt thereof wherein:

$R^{10}$  is  $-NH_2$ ,  $-NH-CH_3$ ,  $-NH-C_2H_5$ ,  $-NH-OCH_3$ , or  $-NH-OC_2H_5$ .

7. A compound of Claim 5 including a pharmaceutical acceptable salt thereof wherein:

$R^{10}$  is  $-NH_2$ ,  $-NH-CH_3$ ,  $-NH-C_2H_5$ ,  $-NH-OCH_3$ , or  $-NH-OC_2H_5$ .

8. A compound of Claim 3 including a pharmaceutically acceptable salt thereof wherein

two of W, Y and X are each  $=N-$  and the other is  $-CH=$ ;

V is  $-NH-$ , or  $-O-$ ;

$R^1$  is hydrogen or methyl;

$R^2$  is alkyl of 1 to 8 carbons;

$R^7$  is hydrogen, methyl, methoxy, Cl, Br, or F;

$R^8$  is hydrogen;

$R^9$  is  $-C(O)R^{10}$ ;

$R^{10}$  is  $-NH_2$ ,  $-NH$ -alkyl,  $-NH$ -alkoxy,  $-NH$ -phenyl, or  $-NH-CH_2$ -phenyl wherein alkyl and alkoxy are of 1 to 6 carbons;

$R^{11}$  is  $-N(R^{12})(R^{13})$  wherein  $N(R^{12})(R^{13})$  taken together form a monocyclic heterocyclyl or substituted heterocyclyl of 5 to 7 atoms containing 1, 2, or 3 additional nitrogen atoms.

9. A compound of Claim 8 including a pharmaceutically acceptable salt thereof wherein:

$R^{10}$  is  $-NH_2$ ,  $-NH-CH_3$ ,  $-NH-C_2H_5$ ,  $-NH-OCH_3$ , or  $-NH-OC_2H_5$ .

10. A compound of Claim 3 including a pharmaceutically acceptable salt thereof wherein:

two of W, Y and X are each  $=N-$  and the other is  $-CH=$ ;

V is -NH-, or -O-;

R<sup>1</sup> is hydrogen or methyl;


R<sup>2</sup> is alkyl of 1 to 8 carbons;

R<sup>7</sup> is hydrogen, methyl, methoxy, Cl, Br, or F;

R<sup>8</sup> is hydrogen;

R<sup>9</sup> is -C(O)R<sup>10</sup>;

R<sup>10</sup> is -NH<sub>2</sub>, -NH-alkyl, -NH-alkoxy, -NH-phenyl, or -NH-CH<sub>2</sub>-phenyl wherein alkyl and alkoxy are of 1 to 6 carbons;




wherein alkyl is of 1 to 4 carbons; and

R<sup>15</sup> and R<sup>16</sup> are independently selected from hydrogen and methyl.


11. A compound of Claim 10 including a pharmaceutically acceptable salt thereof wherein:

R<sup>10</sup> is -NH<sub>2</sub>, -NH-CH<sub>3</sub>, -NH-C<sub>2</sub>H<sub>5</sub>, -NH-OCH<sub>3</sub>, or -NH-OC<sub>2</sub>H<sub>5</sub>.

12. A compound of Claim 4 including a pharmaceutically acceptable salt thereof wherein:



13. A compound of Claim 8 including a pharmaceutically acceptable salt thereof wherein:



14. A pharmaceutical composition comprising as an active ingredient, a compound, or a prodrug or salt thereof, according to claim 1, and a pharmaceutically acceptable carrier.

15. A pharmaceutical composition according to claim 14, further comprising one or more additional active ingredients.

16. A pharmaceutical composition according to claim 15, wherein said additional active ingredient is an anti-inflammatory compound.

17. A pharmaceutical composition according to claim 16, wherein said additional active ingredient is chosen from a steroid and an NSAID.

18. A method of inhibiting TNF- $\alpha$  expression in a mammal, the method comprising administering to the mammal an effective amount of a composition according to Claim 14.

19. A method of treating TNF- $\alpha$  mediated disorder, the method comprising administering to a mammal in need of such treatment, an effective amount of a composition according to Claim 14.

20. The method according to claim 19, wherein the TNF- $\alpha$  mediated disorder is an inflammatory disorder.

21. The method according to claim 19, wherein the TNF- $\alpha$  mediated disorder is chosen from bone resorption, graft vs. host reaction, atherosclerosis, arthritis, osteoarthritis, rheumatoid arthritis, gout, psoriasis, topical inflammatory disease states, adult respiratory distress syndrome, asthma, chronic pulmonary inflammatory disease, cardiac reperfusion injury, renal reperfusion injury, thrombus, glomerulonephritis, Chron's disease, ulcerative colitis, inflammatory bowel disease, multiple sclerosis, endotoxin shock, osteoporosis, Alzheimer's disease, congestive heart failure and cachexia.

22. The method according to claim 19, wherein said composition according to claim 14 is administered with one or more additional anti-inflammatory or immunosuppressive agents as a single dose form or as separate dosage forms.

23. A method of treating a condition associated with TNF- $\alpha$  expression in a mammal, the method comprising administering to a mammal in need of such treatment, an effective amount of a composition according to Claim 14.

24. The method according to claim 23, wherein the condition associated with TNF- $\alpha$  expression is an inflammatory disorder.

25. The method according to claim 23, wherein the condition associated with TNF- $\alpha$  expression is chosen from bone resorption, graft vs. host reaction, atherosclerosis, arthritis, osteoarthritis, rheumatoid arthritis, gout, psoriasis, topical inflammatory disease states, adult respiratory distress syndrome, asthma, chronic pulmonary inflammatory disease, cardiac reperfusion injury, renal reperfusion injury, thrombus, glomerulonephritis, Chron's disease, ulcerative colitis, inflammatory bowel disease, multiple sclerosis, endotoxin shock, osteoporosis, Alzheimer's disease, congestive heart failure and cachexia.

26. The method according to claim 23 wherein said composition according to claim 14 is administered with one or more additional anti-inflammatory or immunosuppressive agents as a single dose form or as separate dosage forms.

27. A method of treating a condition associated with p38 kinase activity in a mammal, the method comprising administering to a mammal in need of such treatment, an effective amount of a composition according to claim 14.

28. The method according to claim 27, wherein the condition associated with p38 kinase activity is an inflammatory disorder.

29. The method according to claim 27, wherein the condition associated with p38 kinase activity is chosen from bone resorption, graft vs. host reaction, atherosclerosis, arthritis, osteoarthritis, rheumatoid arthritis, gout, psoriasis, topical inflammatory disease states, adult respiratory distress syndrome, asthma, chronic pulmonary inflammatory disease, cardiac reperfusion injury, renal reperfusion injury, thrombus, glomerulonephritis, Chron's disease, ulcerative colitis, inflammatory bowel disease, multiple sclerosis, endotoxin shock, osteoporosis, Alzheimer's disease, congestive heart failure and cachexia

30. The method according to claim 27 wherein said composition according to claim 14 is administered with one or more additional anti-inflammatory or immunosuppressive agents as a single dose form or as separate dosage forms.

31. The compound of claim 1 including a pharmaceutically acceptable salt thereof wherein:


two or more of W, X and Y are  $-N=$ .

32. The compound of claim 31 including a pharmaceutically acceptable salt thereof wherein:


V is  $-NH-$  or  $-O-$ ;

$R^1$  is hydrogen or methyl;

$R^2$  is alkyl of 1 to 8 carbons;



$R^{11}$  is  $-N(R^{12})(R^{13})$  wherein  $N(R^{12})(R^{13})$  taken together form a monocyclic heterocyclyl or substituted heterocyclyl of 5 to 7 atoms containing 1, 2 or 3 additional nitrogen atoms,  $-NH$ -alkyl wherein alkyl is of 1 to 4 carbons, or




$R^{15}$  and  $R^{16}$  are independently hydrogen or methyl.

33. The compound of claim 31 including a pharmaceutically acceptable salt thereof wherein:


V is  $-NH-$  or  $-O-$ ;

$R^1$  is hydrogen or methyl;

$R^2$  is alkyl of 1 to 8 carbons;



$R^{11}$  is  $-N(R^{12})(R^{13})$  wherein  $N(R^{12})(R^{13})$  taken together form a monocyclic heterocyclyl or substituted heterocyclyl of 5 to 7 atoms containing 1, 2 or 3 additional nitrogen atoms,  $-NH$ -alkyl wherein alkyl is of 1 to 4 carbons, or




$R^{15}$  and  $R^{16}$  are independently hydrogen or methyl.

34. The compound of claim 31 including a pharmaceutically acceptable salt thereof wherein:


$V$  is  $-NH-$  or  $-O-$ ;

$R^1$  is hydrogen or methyl;

$R^2$  is alkyl of 1 to 8 carbons;



$R^{11}$  is  $-N(R^{12})(R^{13})$  wherein  $N(R^{12})(R^{13})$  taken together form a monocyclic heterocyclyl or substituted heterocyclyl of 5 to 7 atoms containing 1, 2 or 3 additional nitrogen atoms,  $-NH$ -alkyl wherein alkyl is of 1 to 4 carbons, or



$R^{15}$  and  $R^{16}$  are independently hydrogen or methyl.

35. The compound of claim 31 including a pharmaceutically acceptable salt thereof wherein:


$V$  is  $-NH-$  or  $-O-$ ;

$R^1$  is hydrogen or methyl;

$R^2$  is alkyl of 1 to 8 carbons;



$R^{11}$  is  $-N(R^{12})(R^{13})$  wherein  $N(R^{12})(R^{13})$  taken together form a monocyclic heterocyclyl or substituted heterocyclyl of 5 to 7 atoms containing 1, 2 or 3 additional nitrogen atoms,  $-NH$ -alkyl wherein alkyl is of 1 to 4 carbons, or




$R^{15}$  and  $R^{16}$  are independently hydrogen or methyl.

36. The compound of claim 31 including a pharmaceutically acceptable salt thereof wherein:


$V$  is  $-NH-$  or  $-O-$ ;

$R^1$  is hydrogen or methyl;

$R^2$  is alkyl of 1 to 8 carbons;



$R^{11}$  is  $-N(R^{12})(R^{13})$  wherein  $N(R^{12})(R^{13})$  taken together form a monocyclic heterocyclyl or substituted heterocyclyl of 5 to 7 atoms containing 1, 2 or 3 additional nitrogen atoms,  $-NH$ -alkyl wherein alkyl is of 1 to 4 carbons, or




$R^{15}$  and  $R^{16}$  are independently hydrogen or methyl.

37. The compound of claim 31 including a pharmaceutically acceptable salt thereof wherein:


$V$  is  $-NH-$  or  $-O-$ ;

$R^1$  is hydrogen or methyl;

$R^2$  is alkyl of 1 to 8 carbons;



$R^{11}$  is  $-N(R^{12})(R^{13})$  wherein  $N(R^{12})(R^{13})$  taken together form a monocyclic heterocyclyl or substituted heterocyclyl of 5 to 7 atoms containing 1, 2 or 3 additional nitrogen atoms,  $-NH$ -alkyl wherein alkyl is of 1 to 4 carbons, or




$R^{15}$  and  $R^{16}$  are independently hydrogen or methyl.

38. The compound of claim 31 including a pharmaceutically acceptable salt thereof wherein:


$V$  is  $-NH-$  or  $-O-$ ;

$R^1$  is hydrogen or methyl;

$R^2$  is alkyl of 1 to 8 carbons;



$R^{11}$  is  $-N(R^{12})(R^{13})$  wherein  $N(R^{12})(R^{13})$  taken together form a monocyclic heterocyclyl or substituted heterocyclyl of 5 to 7 atoms containing 1, 2 or 3 additional nitrogen atoms,  $-NH$ -alkyl wherein alkyl is of 1 to 4 carbons, or



$R^{15}$  and  $R^{16}$  are independently hydrogen or methyl.


39. The compound of claim 31 including a pharmaceutically acceptable salt thereof wherein:




V is -NH- or -O-;

R<sup>1</sup> is hydrogen or methyl;

R<sup>2</sup> is alkyl of 1 to 8 carbons;



R<sup>11</sup> is -N(R<sup>12</sup>)(R<sup>13</sup>) wherein N(R<sup>12</sup>)(R<sup>13</sup>) taken together form a monocyclic heterocyclyl or substituted heterocyclyl of 5 to 7 atoms containing 1, 2 or 3 additional nitrogen atoms, -NH-alkyl wherein alkyl is of 1 to 4 carbons, or




R<sup>15</sup> and R<sup>16</sup> are independently hydrogen or methyl.

40. The compound of claim 31 including a pharmaceutically acceptable salt thereof wherein:


V is -NH- or -O-;

R<sup>1</sup> is hydrogen or methyl;

R<sup>2</sup> is alkyl of 1 to 8 carbons;



R<sup>11</sup> is -N(R<sup>12</sup>)(R<sup>13</sup>) wherein N(R<sup>12</sup>)(R<sup>13</sup>) taken together form a monocyclic heterocyclyl or substituted heterocyclyl of 5 to 7 atoms containing 1, 2 or 3 additional nitrogen atoms, -NH-alkyl wherein alkyl is of 1 to 4 carbons, or




R<sup>15</sup> and R<sup>16</sup> are independently hydrogen or methyl.

41. The compound of claim 31 including a pharmaceutically acceptable salt thereof wherein:


V is -NH- or -O-;

R<sup>1</sup> is hydrogen or methyl;

R<sup>2</sup> is alkyl of 1 to 8 carbons;



R<sup>11</sup> is -N(R<sup>12</sup>)(R<sup>13</sup>) wherein N(R<sup>12</sup>)(R<sup>13</sup>) taken together form a monocyclic heterocyclyl or substituted heterocyclyl of 5 to 7 atoms containing 1, 2 or 3 additional nitrogen atoms, -NH-alkyl wherein alkyl is of 1 to 4 carbons, or



R<sup>15</sup> and R<sup>16</sup> are independently hydrogen or methyl.

## INTERNATIONAL SEARCH REPORT

Inte      1al Application No  
PCT/US 00/35289

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7    C07D237/04    A61K31/505    A61P29/00    C07D401/12    A61K31/53  
          C07D403/04    A61K31/55    C07D403/12

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7    C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BEILSTEIN Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,A	EP 0 969 004 A (3V SIGMA SPA) 5 January 2000 (2000-01-05) claim 1	2-17, 31-41
A	WO 99 01442 A (POYSER JEFFREY PHILIP ;TIMMS DAVID (GB); TELFORD BERWICK (GB); ZEN) 14 January 1999 (1999-01-14) claim 1	2-17, 31-41
A	US 5 840 893 A (BUKRINSKY MICHAEL I ET AL) 24 November 1998 (1998-11-24) examples 1B,1C	2-17, 31-41
Y	WO 98 24782 A (AMGEN INC ;MANTLO NATHAN B (US); SPOHR ULRIKE D (US); MALONE MICHA 11 June 1998 (1998-06-11) claim 1	2-41
	--- -/-	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

## \* Special categories of cited documents :

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*G\* document member of the same patent family

Date of the actual completion of the international search

4 April 2001

Date of mailing of the international search report

8. 04. 01

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+31-70) 340-3016

Authorized officer

Gettins, M

## INTERNATIONAL SEARCH REPORT

Int: al Application No

PCT/US 00/35289

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 834 507 A (JANSSEN PHARMACEUTICA NV) 8 April 1998 (1998-04-08) claim 1	2-17, 31-41
P,Y	FUJIWARA N ET AL: "Synthesis and bioactivities of novel piperidylpyrimidine derivatives: inhibitors of tumor necrosis factor-alpha production" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,GB,OXFORD, vol. 10, no. 12, June 2000 (2000-06), pages 1317-1320, XP004206996 ISSN: 0960-894X tables 3,4	2-41

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 00/35289

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
Although claims 18-30 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☒ Claims Nos.: 1  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1

Present claim 1 relates to an extremely large number of possible compounds/. Support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT is to be found, however, for only a very small proportion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to the compounds in which at least 2 of W, Y and X are =N-; Z is as in claim 2 i.e. limited to amino or thioether derivatives, R9 is as in claim 2 i.e. -C(O)R10 and R11 is as in claim 2 i.e. N(R12)(R13). This encompasses all of the examples.

Present claim 14 relates to a prodrugs i.e. compounds defined by reference to a desirable characteristic or property, namely their ability to be converted to compounds of formula I

Claim 14 covers all compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds. In the present case, the claim so lacks support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claim also lacks clarity (Article 6 PCT). An attempt is made to define the compounds by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claim which appear to be clear, supported and disclosed, namely those parts relating to the compounds I. Prodrugs have not been searched.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/35289

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0969004 A	05-01-2000	IT MI981266 A	06-12-1999
WO 9901442 A	14-01-1999	NONE	
US 5840893 A	24-11-1998	US 5733932 A	31-03-1998
		US 5574040 A	12-11-1996
		AU 715844 B	10-02-2000
		AU 4755996 A	24-07-1996
		CA 2218561 A	11-07-1996
		EP 0865434 A	23-09-1998
		WO 9620932 A	11-07-1996
		US 5620983 A	15-04-1997
		US 5703086 A	30-12-1997
WO 9824782 A	11-06-1998	AU 5525498 A	29-06-1998
		AU 6012098 A	29-06-1998
		BG 103512 A	31-07-2000
		BG 103521 A	31-07-2000
		BR 9713850 A	29-02-2000
		BR 9713863 A	14-03-2000
		CN 1246857 A	08-03-2000
		CN 1246858 A	08-03-2000
		CZ 9902015 A	17-11-1999
		CZ 9902016 A	17-11-1999
		EP 0948496 A	13-10-1999
		EP 0948497 A	13-10-1999
		WO 9824780 A	11-06-1998
EP 0834507 A	08-04-1998	AU 3926697 A	09-04-1998
		BR 9704937 A	06-06-2000
		CA 2216486 A	01-04-1998
		CN 1180698 A	06-05-1998
		CZ 9702993 A	11-11-1998
		HR 970526 A	31-10-1998
		HU 9701596 A	28-06-1999
		JP 10114759 A	06-05-1998
		NO 974368 A	02-04-1998
		PL 322369 A	14-04-1998
		SG 53075 A	28-09-1998
		SK 131997 A	11-06-1999
		TR 9701070 A	21-04-1998
		TW 411335 B	11-11-2000
		ZA 9708766 A	30-03-1999